CA2708613A1 - Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith - Google Patents

Abstract

Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.

Description

SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN
KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE
INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH
CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This patent application claims priority to U.S. provisional application Serial No. 61/012,506, filed on December 10, 2007. The contents of the priority application are incorporated herein by reference in their entirety as though fully set forth herein.

BACKGROUND OF THE INVENTION
Field of the Invention [002] The present invention relates generally to methods and compositions that can be used to treat or inhibit cancers, angiogenesis, and modulate their associated inflammatory pathways susceptible to protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

Description of the Related Art [003] Signal transduction provides an overarching regulatory mechanism important to maintaining normal homeostasis or, if dysregulated, acting as a causative or contributing mechanism associated with numerous disease pathologies and conditions.
At the cellular level, signal transduction refers to the movement of a signal or signaling moiety within the cell or from outside of the cell to the cell interior. The signal, upon reaching its receptor target, may initiate ligand-receptor interactions requisite to many cellular events, some of which may further act as a subsequent signal. Such interactions serve not only as a series cascade, but also are part of an intricate interacting network or web of signal events capable of providing fine-tuned control of homeostatic processes.
This network however can become dysregulated, thereby resulting in an alteration in cellular activity and changes in the program of genes expressed within the responding cell. See, for example, Figure 1, which displays a simplified version of the interacting kinases regulating regulating the NF-KB signal transduction pathway.

SUBSTITUTE SHEET (RULE 26) 10041 Signal transducing receptors are generally divided into three classes.
The first class of receptors are receptors that penetrate the plasma membrane and have some intrinsic enzymatic activity. Representative receptors that have intrinsic enzymatic activities include those that are tyrosine kinases (e.g. PDGF, insulin, EGF and FGF
receptors), tyrosine phosphatases (e.g. CD45 [cluster determinant-45] protein of T cells and macrophages), guanylate cyclases (e.g. natriuretic peptide receptors) and serine/threonine kinases (e.g. activin and TGF-[3 receptors). Receptors with intrinsic tyrosine kinase activity are capable of autophosphorylation as well as phosphorylation of other substrates.

[005] Receptors of the second class are those that are coupled, inside the cell, to GTP-binding and hydrolyzing proteins (termed G-proteins). Receptors of this class that interact with G-proteins have a structure that is characterized by 7 transmembrane spanning domains. These receptors are termed serpentine receptors. Examples of this class are the adrenergic receptors, odorant receptors, and certain hormone receptors (e.g.
glucagon, angiotensin, vasopressin and bradykinin).

10061 The third class of receptors may be described as receptors that are found intracellularly and, upon ligand binding, migrate to the nucleus where the ligand-receptor complex directly affects gene transcription.

10071 The proteins that function as receptor tyrosine kinases (RTK) contain four major domains, those being: a) a transmembrane domain, b) an extracellular ligand binding domain, c) an intracellular regulatory domain, and d) an intracellular tyrosine kinase domain. The amino acid sequences of RTKs are highly conserved with those of cAMP-dependent protein kinase (within the ATP and substrate binding regions). RTK
proteins are classified into families based upon structural features in their extracellular portions, which include the cysteine rich domains, immunoglobulin-like domains, cadherin domains, leucine-rich domains, Kringle domains, acidic domains, fibronectin type III
repeats, discoidin I-like domains, and EGF-like domains. Based upon the presence of these various extracellular domains the RTKs have been sub-divided into at least 14 different families.
1008] Many receptors that have intrinsic tyrosine kinase activity upon phosphorylation interact with other proteins of the signaling cascade. These other proteins contain a domain of amino acid sequences that are homologous to a domain first identified in the c-Src proto-oncogene. These domains are termed SH2 domains.

(2) [009] The interactions of SH2 domain containing proteins with RTKs or receptor associated tyrosine kinases leads to tyrosine phosphorylation of the SH2 containing proteins. The resultant phosphorylation produces an alteration (either positively or negatively) in that activity. Several SH2 containing proteins that have intrinsic enzymatic activity include phospholipase C-y (PLC-y), the proto-oncogene c-Ras associated GTPase activating protein (rasGAP), phosphatidylinositol-3-kinase (P13K), protein tyrosine phosphatase-1 C (PTP I C), as well as members of the Src family of protein tyrosine kinases (PTKs).

[0010] Non-receptor protein tyrosine kinases (PTK) by and large couple to cellular receptors that lack enzymatic activity themselves. An example of receptor-signaling through protein interaction involves the insulin receptor (IR). This receptor has intrinsic tyrosine kinase activity but does not directly interact, following autophosphorylation, with enzymatically active proteins containing SH2 domains (e.g. P13K or PL,C-y).
Instead, the principal IR substrate is a protein termed IRS-l.

[0011] The receptors for the TGF-[3 superfamily represent the prototypical receptor serine/threonine kinase (RSTK). Multifunctional proteins of the TGF- [3 superfamily include the activins, inhibins and the bone morphogenetic proteins (BMPs).
These proteins can induce and/or inhibit cellular proliferation or differentiation and regulate migration and adhesion of various cell types. One major effect of TGF-3 is a regulation of progression through the cell cycle. Additionally, one nuclear protein involved in the responses of cells to TGF-(3 is c-Myc, which directly affects the expression of genes harboring Myc-binding elements. PKA, PKC, and MAP kinases represent three major classes of non-receptor serine/threonine kinases.

[0012] The relationship between kinase activity and disease states is currently being investigated in many laboratories. Such relationships may be either causative of the disease itself or intimately related to the expression and progression of disease associated symptomology. Rheumatoid arthritis, an autoimmune disease, provides one example where the relationship between kinases and the disease are currently being investigated.

[0013] Rheumatoid arthritis (RA) is the most prevalent and best studied of the autoimmune diseases and afflicts about I% of the population worldwide, and for unknown reasons, like other autoimmune diseases, is increasing. RA is characterized by chronic (3) synovial inflammation resulting in progressive bone and cartilage destruction of the joints.
Cytokines, chemokines, and prostaglandins are key mediators of inflammation and can be found in abundance both in the joint and blood of patients with active disease. For example, PGE2 is abundantly present in the synovial fluid of RA patients. Increased PGE2 levels are mediated by the induction of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) at inflamed sites. [See, for example van der Kraan PM and van den Berg WB.
Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care,3:205-211, 2000; Choy EHS and Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med. 344:907-916, 2001; and Wong BR, et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-762, 2004.]

100141 The etiology and pathogenesis of RA in humans is still poorly understood, but is viewed to progress in three phases. The initiation phase occurs where dendritic cells present self antigens to autoreactive T cells. The T cells activate autoreactive B cells via cytokines resulting in the production of autoantibodies, which in turn form immune complexes in joints. In the effector phase, the immune complexes bind Fcf receptors on macrophages and mast cells, resulting in release of cytokines and chemokines causing inflammation and pain. In the final phase, cytokines and chemokines activate and recruit synovial fibroblasts, osteoclasts and polymorphonuclear neutrophils that release proteases, acids, and ROS such as 02-, resulting in irreversible cartilage and bone destruction.

[0015] In the collagen-induced R.A animal model, the participation of T and B
cells is required to initiate the disease. B cell activation signals through spleen tyrosine kinase (Syk) and phosphoinositide 3-kinase (P13K) following antigen receptor triggering [Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
Curr Opin Pharmacol. Aug;3(4):426.-34, (2003)]. After the engagement of antigen receptors on B cells, Syk is phosphorylated on three tyrosines. Syk is a 72-kDa protein-tyrosine kinase that plays a central role in coupling immune recognition receptors to multiple downstream signaling pathways. This function is a property of both its catalytic activity and its ability to participate in interactions with effector proteins containing SH2 domains.
Phosphorylation of Tyr-317, -342, and -346 create docking sites for multiple SH2 domain containing proteins. [Hutchcroft, J. E., Harrison, M. L. & Geahlen, R. L.
(1992).
Association of the 72-kDa protein-tyrosine kinase Ptk72 with the B-cell antigen receptor. J.

(4) Biol. Chem. 267: 8613-8619, (1992) and Yamada, T., Taniguchi, T., Yang, C., Yasue, S., Saito, H. & Yamamura, H. Association with B-cell antigen cell antigen receptor with protein-tyrosine kinase-P72(Syk) and activation by engagement of membrane IgM.
Eur. J.
Biochem. 213: 455--459,(1993)].

[00161 Syk has been shown to be required for the activation of P13K in response to a variety of signals including engagement of the B cell antigen receptor (BCR) and macrophage or neutrophil Fc receptors. [See Crowley, M. T., el al,. J. Exp.
Med. 186:
1027-1039, (1997); Raeder, E. M., et al., J. Immunol. 163, 6785-6793, (1999);
and Jiang, K., et al., Blood 101, 236-244, (2003)]. In B cells, the BCR-stimulated activation of P13K
can be accomplished through the phosphorylation of adaptor proteins such as BCAP, CD 19, or Gabl, which creates binding sites for the p85 regulatory subunit of P13K.
Signals transmitted by many IgG receptors require the activities of both Syk and P13K
and their recruitment to the site of the clustered receptor. In neutrophils and monocytes, a direct association of P13K with phosphorylated immunoreceptor tyrosine based activation motif sequences on FcgRIIA was proposed as a mechanism for the recruitment of P13K
to the receptor. And recently a direct molecular interaction between Syk and P13K has been reported [Moon KD, et al., Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase. J. Biol. Chem. 280, No.
2, Issue of January 14, pp. 1543-1551, (2005)].

[0017] The precise mechanisms for the chemopreventive effects of NSAIDs are not yet known, however the ability of these drugs to induce inhibition of cell proliferation, inhibition of angiogenesis, and induction of apoptosis is well known [7 Shiff, S. J., and Rigas, B. (1997) Gastroenterology 113, 1992-1998 and Elder, D. J. E., and Paraskeva, C.
(1999) Apoptosis 4, 365-372].

[0018] The most characterized target for NSAIDs is cyclooxygenase (COX), which catalyzes the synthesis of prostaglandins from arachidonic acid. There are two known COX
isoforms, COX-1 and COX-2. COX-1 is a constitutively expressed enzyme found in most tissues and remains unaltered in colorectal cancer, while COX-2 expression can be up-regulated by a variety of cytokines, hormones, phorbol esters, and oncogenes in colorectal adenomas and adenocarcinomas [Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F.
M., Ferrenbach, S., and DuBois, R. N. (1994) Gastroenterology 107, 1183-1188].

(5) 100191 The molecular basis of the chemopreventive effects of NSAIDs for colon cancer has been attributed at least in part to inhibition of COX-2 by induction of the susceptibility of cancer cells to apoptosis [Rigas, B., and Shiff, S. J.
(2000) Med.
Hypotheses 54, 210-215]. A null mutation of COX-2 in a murine model of familial adenomatous polyposis, restored apoptosis and reduced the size and the number of colorectal adenomas [Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. (1996) Cell 87, 803-809].
Similar regression of adenomas has been observed by treatment of Min mouse with the NSAID sulindac [Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C.,Duhamel, 0., Trousset, M., and Attali, P. (1991) Gastroenterology 101,635-639].
[0020] However, observations relating to the proapoptotic effect of NSAIDs lead to contradictory conclusions and demonstrate that they act via COX-dependent and COX-independent mechanisms [Rigas, B., and Shiff, S. J. (2000) Med. Hypotheses 54, 210-215].
For example, the addition of exogenous prostaglandins to a colon cancer cell line that lacks COX activity cannot reverse the proapoptotic effect of sulindac sulfide, a metabolite derived from sulindac [Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., and Rigas, B. (1996) Biochem. Pharmacol. 52, 237-245].

100211 Also, sulindac sulfone, another sulindac metabolite that does not inhibit COXs, affects tumor growth in animal models [Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T.,Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J.,Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R.
(1997) CancerRes.
57, 2909-2915] and induces apoptosis in cultured cancer cells expressing or not expressing COXs.

100221 Hence, a wide body of evidence now exists demonstrating that molecular targets of NSAIDs in addition to COX-1 and COX-2 exist and provide a link between the chemoprotective effect of NSAIDs on cancer cells and their level of COX
expression.
Recent studies have identified a series of new molecular targets for NSAIDS
mainly involved in signaling pathways including the extracellular signal -regulated kinase 1/2 signaling [Rice, P. L., Goldberg, R. J., Ray, E. C., Driggers, L. J., and Ahnen, D. J.
(2001)Cancer Res. 61, 1541-1547), NF-_B (21. Kopp, E., and Ghosh, S. (1994) Science 265, 956-959), p70S6 kinase ( Law, B. K., Waltner-Law, M. E., Entingh, A. J., Chytil, A., Aakre, M. E., Norgaard, P., and Moses, H. L. (2000) J Biol. Chem. 275, 38261-38267), (6) p2lras signaling (Herrmann, C., Block, C., Geisen, C., Haas, K., Weber, C., Winde, G., Moroy, T., and Muller, O. (1998) Oncogene 17, 1769-1776), and Akt/PKB kinase (Hsu, A.
L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M., and Chen, C. S.
(2000) J. Biol.
Chem. 275, 11397-11403]

[0023] Much research has shown that inhibitors of COX-2 activity result in decreased production of PGE2 and are effective in pain relief for patients with chronic arthritic conditions such as RA. However, concern has been raised over the adverse effects of agents that inhibit COX enzyme activity since both COX-1 and COX-2 are involved in important maintenance functions in tissues such as the gastrointestinal and cardiovascular systems. Therefore, designing a safe, long term treatment approach for pain relief in these patients is necessary. Since inducers of COX-2 and iNOS synthesis signal through the Syk, P13K, p38, ERK1/2, and NF-kB dependent pathways, inhibitors of these pathways may be therapeutic in autoimmune conditions and in particular in the inflamed and degenerating joints of RA patients.

[0024] Other kinases currently being investigated for their association with disease symptomology include Aurora, FGFR, MSK, Rse, and Syk.

[0025] Aurora - important regulators of cell division, are a family of serine/threonine kinases includeing Aurora A, B and C. Aurora A and B kinases have been identified to have direct but distinct roles in mitosis. Over-expression of these three isoforms have been linked to a diverse range of human tumor types, including leukemia, colorectal, breast, prostate, pancreatic, melanoma and cervical cancers.

[0026] Fibroblast growth factor receptor (FGFR) is a receptor tyrosine kinase.
Mutations in this receptor can result in constitutive activation through receptor dimerization, kinase activation, and increased affinity for FGF. FGFR has been implicated in achondroplasia, angiogenesis, and congenital diseases.

100271 MSK (mitogen- and stress-activated protein kinase) 1 and MSK2 are kinases activated downstream of either the ERK (extracellular-signal-regulated kinase) 1/2 or p38 MAPK (mitogen-activated protein kinase) pathways in vivo and are required for the phosphorylation of CREB (cAMP response element-binding protein) and histone H3.

(7) [0028] Rse is mostly highly expressed in the brain. Rse, also known as Brt, BYK, Dtk, Etk3, Sky, Tif, or sea-related receptor tyrosine kinase, is a receptor tyrosine kinase whose primary role is to protect neurons from apoptosis. Rse, Axl, and Mer belong to a newly identified family of cell adhesion molecule-related receptor tyrosine kinases. GAS6 is a ligand for the tyrosine kinase receptors Rse, Axl, and Mer. GAS6 functions as a physiologic anti-inflammatory agent produced by resting EC and depleted when pro-inflammatory stimuli turn on the pro-adhesive machinery of EC.

[0029] Glycogen synthase kinase-3 (GSK-3), present in two isoforms, has been identified as an enzyme involved in the control of glycogen metabolism, and may act as a regulator of cell proliferation and cell death. Unlike many serine-threonine protein kinases, GSK-3 is constitutively active and becomes inhibited in response to insulin or growth factors. Its role in the insulin stimulation of muscle glycogen synthesis makes it an attractive target for therapeutic intervention in diabetes and metabolic syndrome.

[0030] GSK-3 dysregulation has been shown to be a focal point in the development of insulin resistance. Inhibition of GSK3 improves insulin sensitivity not only by an increase of glucose disposal rate but also by inhibition of gluconeogenic genes such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in hepatocytes.
Furthermore, selective GSK3 inhibitors potentiate insulin-dependent activation of glucose transport and utilization in muscle in vitro and in vivo. GSK3 also directly phosphorylates serine/threonine residues of insulin receptor substrate-1, which leads to impairment of insulin signaling. GSK3 plays an important role in the insulin signaling pathway and it phosphorylates and inhibits glycogen synthase in the absence of insulin [Parker, P. J., Caudwell, F. B., and Cohen, P. (1983) Eur. J. Biochem. 130:227-234].
Increasing evidence supports a negative role of GSK-3 in the regulation of skeletal muscle glucose transport activity. For example, acute treatment of insulin-resistant rodents with selective GSK-3 inhibitors improves whole-body insulin sensitivity and insulin action on muscle glucose transport. Chronic treatment of insulin-resistant, pre-diabetic obese Zucker rats with a specific GSK-3 inhibitor enhances oral glucose tolerance and whole-body insulin sensitivity, and is associated with an amelioration of dyslipidemia and an improvement in IRS-1-dependent insulin signaling in skeletal muscle. These results provide evidence that selective targeting of GSK-3 in muscle may be an effective intervention for the treatment of obesity-associated insulin resistance.

(8) [0031] Syk is a non-receptor tyrosine kinase related to ZAP-70 that isinvolved in signaling from the B-cell receptor and the IgE receptor. Syk binds to ITAM
motifs within these receptors, and initiates signaling through the Ras, P13K, and PLCg signaling pathways. Syk plays a critical role in intracellular signaling and thus is an important target for inflammatory diseases and respiratory disorders.

[0032] Angiogenesis is the process of vascularization of a tissue involving the development of new capillary blood vessels. The regulation and control of angiogenesis is important to numerous disease states associated with such ocular disorders as macular degeneration or diabetic retinopathy. Additionally, angiogenesis is a key component for successful metastatic cancer dissemination and survival.

10033] A number of protein kinases have been implicated in the angiogenic process.
For example, recent work has identified the PI3K-Akt-PTEN signaling node as an intercept point for the control of angiogenesis in brain tumors [Castellino RC and Durden DL., Mechanisms of Disease: the PI3K.-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 3(12):682-93, 2007] See also [Blackburn JS, et al., RNA interference inhibition of matrix metalloproteinase-I
prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis, Cancer Res. 67(22):10849-58 2007]. Additionally, for example, Lee and colleagues have demonstrated the relation of AKT angiogenesis in a human gastric colon cancer model [Lee, BL., et al., A hypoxia-independent up regulation of hypoxia-inducible factor-I
by Akt contributes to angiogenesis in human gastric cancer. Carcinogenesis. 2007 Nov 4.

[0034] Therefore, it would be useful to identify methods and compositions that would modulate the expression or activity of single or multiple selected kinases. The realization of the complexity of the relationship and interaction among and between the various protein kinases and kinase pathways reinforces the pressing need for developing pharmaceutical agents capable of acting as protein kinase modulators, regulators or inhibitors that have beneficial activity on multiple kinases or multiple kinase pathways. A
single agent approach that specifically targets one kinase or one kinase pathway may be inadequate to treat very complex diseases, conditions and disorders, such as, for example, diabetes and metabolic syndrome. Modulating the activity of multiple kinases may additionally generate synergistic therapeutic effects not obtainable through single kinase modulation.

(9) [0035] Such modulation and use may require continual use for chronic conditions or intermittent use, as needed for example in inflammation, either as a condition unto itself or as an integral component of many diseases and conditions. Additionally, compositions that act as modulators of kinase can affect a wide variety of disorders in a mammalian body. I
[0036] Currently, there is a trend favoring the development of multi-targeted treatment modalities for disease conditions thereby providing the potential for enhanced responsiveness with a concommitant potential to reduce the potential toxicities associated with aggressive treatment agains a single target. See [Arbiser, JL., Why targeted therapy hasn't worked in advanced cancer., J. Clin. Invest., 117(10): 2762-65, 2007, and Ma, WW
and Hildalgo, M., Exploiting novel molecular targets in gastrointestinal cancers. World J
Gastroenterol. 13(44): 5845 - 56,2007] The instant invention describes substituted 1,3-cyclopentadione compounds that may be used to regulate the activity of multiple kinases, thereby providing a means to treat numerous disease related symptoms with a concomitant increase in the quality of life.

SUMMARY OF THE INVENTION

[0037] The present invention relates generally to methods and compositions that can he used to treat or inhibit angiogenesis, cancers and their associated inflammatory pathways susceptible to protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

[0038] A first embodiment of the invention describes methods to treat a cancer responsive to protein kinase modulation in a mammal in need. The method comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.

[0039] A second embodiment of the invention describes compositions to treat a cancer responsive to protein kinase modulation in a mammal in need where the composition comprises a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where the therapeutically effective amount modulates a cancer associated protein kinase.

[0040] A third embodiment of the invention describes methods to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need. The method (10) comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyelopentadione compound.

[00411 A further embodiment of the invention describes compositions to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need where the composition comprises a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where the therapeutically effective amount modulates an angiogenic associated protein kinase.

[0042] Another embodiment describes methods to modulate inflammation associated with cancer or angiogenesis. The method comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound [0043] Compositions for treating inflammation associated with angiogenesis or cancer are described in another embodiment of the invention. Here the compositions comprise a therapeutically effective amount of a substituted 1,3-cyclopentadione compound where the therapeutically effective amount modulates inflammation associated protein kinases.

[0044] In one embodiment, the invention describes a composition to treat a cancer or angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition incldues a therapeutically effective amount of a cis-n-tetrahydro-isoalpha acid (TH5) as the only substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates a cancer associated protein kinase or an angiogenesis associated protein kinase.

[0045] In one embodiment, the invention describes a composition to treat a cancer or angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amounts of one or more (n) analogs of substituted 1,3-cyclopentadione compound and optionally one or more (ad) analogs of substituted 1,3-cyclopentadione compound in the composition;
wherein said therapeutically effective amount modulates a cancer associated protein kinase or an angiogenesis associated protein kinase.

[0046] In one embodiment, the invention describes a composition to treat a cancer pr angiogenic conditions responsive to protein kinase modulation in a mammal in need (11) thereof, said composition consisting essentially of therapeutically effective amount of one or more (co) analogs of substituted 1,3-cyclopentadione compound in the composition;
wherein said therapeutically effective amount modulates a cancer associated protein kinase or an angiogenesis associated protein kinase.

10047] In one embodiment, the invention describes a composition to treat a cancer or angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition incldues a therapeutically effective amount of only one analog of a substituted 1,3-cyclopentadione compound; wherein said therapeutically effective amount modulates a cancer associated protein kinase or an angiogenesis associated protein kinase.
10048] In one embodiment, the invention describes a composition to treat a cancer or angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition includeds one or more of the substituted 1,3-cyclopentadione compounds selected from the group consisting of rho (6S) cis n iso-alpha acid, rho (6S) cis n iso-alpha acid, rho (6R) cis n iso-alpha acid, rho (6R) trans n iso-alpha acid, rho (6S) trans n iso-alpha acid, rho (6R) cis rho n iso-alpha acid, rho (6S) cis n iso-alpha acid, (6S) trans rho n iso-alpha acid, rho (6R) trans n iso-alpha acid, rho (6S) cis co iso-alpha acid, rho (6R) cis co iso-alpha acid, rho (6R) trans co iso-alpha acid, rho (6S) trans co iso-alpha acid, rho (6R) cis co iso-alpha acid, rho (6S) cis co iso-alpha acid, rho (6S) trans co iso-alpha acid, rho (6R) trans co iso-alpha acid, rho (6S) cis ad iso-alpha acid, rho (6R) cis ad iso-alpha acid, rho (6R) trans ad iso-alpha acid, rho (6S) trans ad iso-alpha acid, rho (6R) cis ad iso-alpha acid, rho (6S) cis ad iso-alpha acid, rho (6S) trans ad iso-alpha acid, rho (6R) trans ad iso-alpha acid, tetrahydro cis n iso-alpha acid, tetrahydro trans n iso-alpha acid, tetrahydro cis n iso-alpha acid, tetrahydro trans n iso-alpha acid, tetrahydro cis co iso-alpha acid, tetrahydro trans co iso-alpha acid, tetrahydro cis co iso-alpha acid, tetrahydro trans co iso-alpha acid, tetrahydro cis ad iso-alpha acid, tetrahydro trans ad iso-alpha acid, tetrahydro cis ad iso-alpha acid, tetrahydro trans ad iso-alpha acid, hexahydro (6S) cis n iso-alpha acid, hexahydro (6R) cis n iso-alpha acid, hexahydro (6R) trans n iso-alpha acid, hexahydro (6S) trans n iso-alpha acid, hexahydro (6R) cis n iso-alpha acid, hexahydro (6S) cis n iso-alpha acid, hexahydro (6S) trans n iso-alpha acid, hexahydro (6R) trans n iso-alpha acid , hexahydro (6S) cis co iso-alpha acid, hexahydro (6R) cis co iso-alpha acid, hexahydro (6R) trans co iso-alpha acid, hexahydro (6S) trans co iso-alpha acid, hexahydro (6R) cis co iso-alpha acid, hexahydro (6S) cis co iso-alpha acid, hexahydro (6S) trans co iso-alpha acid, (12) hexahydro (6R) trans co iso-alpha acid, hexahydro (6S) cis ad iso-alpha acid, hexahydro (6R) cis ad iso-alpha acid, hexahydro (6R) trans ad iso-alpha acid, hexahydro (6S) trans ad iso-alpha acid, hexahydro (6R) cis ad iso-alpha acid, hexahydro (6S) cis ad iso-alpha acid, hexahydro (6S) trans ad iso-alpha acid, hexahydro (6R) trans ad iso-alpha acid, lupolone, colupulone, adlupulone, prelupulone, postlupulone, and xanthohumol.

BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 graphically depicts a portion of the kinase network regulating NF-i B in relation to cancer, angiogenesis and inflammation.

[0050] Figure 2 depicts the chemical structure of individual members forming Meta-THc.

[0051] Figure 3 depicts a representative chromatogram of a Meta-THc composition.
The top panel identifies the chromatagraphic peaks comprising the Meta-THc components of the mixture whereas the subsequent panels describe the chromatagraphic profile of the isolation fractions comprising the peaks.

[0052] Figure 4 depicts the inhibitory effects of Meta-THc on P13K and assorted kinases associated with cancer, angiogenesis, and inflammation..

[0053] Figure 5 provides a graphic representation of the inhibition of PGEZ
and nitric oxide production in LPS activated RAW 264.7 cells by Meta-THc.

[0054] Figure 6 provides a graphic representation of the inhibition of COX-2 protein expression in RAW 264.7 cells by Meta-THc.

[0055] Figure 7 provides a graphic representation demonstrating that Meta-THc did not inhibit PGEZ production by preformed COX-2 LPS activated RAW 264.7 cells.

[0056] Figure 8 provides a representative Western blot analysis showing inhibition by Meta-THc of NF-KB binding in LPS activated RAW 264.7 cell nuclear extract.

[0057] Figure 9 graphically depicts the inhibition by Meta-THc of TNFa and IL

induced MMP-13 expression in the SW1353 human chondrosarcoma cell line (13) [00581 Figure 10 graphically displays the inhibitory effects of Meta-THc analogs on PGE2 and nitric oxide production in LPS activated RAW 264.7 cells.

100591 Figure 11 provides a graphic representation depicting the inhibitory effect of Meta-THc analogs on MAPK1 kinase.

100601 Figure 12 is a graphic representation depicting the inhibitory effect of Meta-THc analogs on a panel of inflammation associated kinases.

100611 Figure 13 provides a graphic representation depicting the inhibitory effect of Meta-THc analogs on GSK kinase.

[00621 Figure 14 is a graphic representation of the effect of Meta-THc analogs on the angiogenesis associated kinase Arg Tyrosine kinase.

[00631 Figure 15 depicts the effects of Meta-THc analogs on a panel of kinases involved in colon cancer progression.

[00641 Figure 16 graphically depicts the effects of Meta-THc on the arthritic index in a murine model of rheumatoid arthritis.

[00651 Figure 17 graphically depicts the effects of Meta-THc analogs on the growth of HT-29, Caco-2 and SW480 colon cancer cell lines.

[00661 Figure 18 graphically displays the detection of Meta- THc in the serum over time following ingestion of 940 mg of Meta-THc in humans.

[00671 Figure 19 displays the profile of Meta-THc detectable in the serum versus control.

100681 Figure 20 depicts the metabolism of Meta-THc by CYP2C9* 1.

[00691 Figure 21 depicts chemical structures of beta acids: lupulone, colupulone, adlupulone, prelupulone and postlupuline.

100701 Figure 22 depicts the chemical structure of xanthohumol.

100711 Figure 23 shows the gini coefficients for different THs (tetrahydroisoalpha acids).

(14) [00721 Figure 24 shows a comparison between the Gini coefficients of TH 1-7 and other kinase drugs on over 200 human protein kinases.

DETAILED DESCRIPTION OF THE INVENTION

[00731 The present invention relates generally to methods and compositions that are used to treat or inhibit angiogenesis, cancers and their associated inflammatory pathways susceptible to protein kinase modulation. More specifically, the invention relates to methods and compositions that utilize substituted 1,3-cyclopentadione compounds.

[00741 The patents, published applications, and scientific literature referred to herein establish the knowledge of those with skill in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the latter.
Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

[0075] Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of recombinant DNA technology include Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989); Kaufman el al., Eds., Handbook of Molecular and Cellular Methods in Biology in Medicine, CRC
Press, Boca Raton (1995); McPherson, Ed., Directed Mutagenesis: A Practical Approach, IRL
Press, Oxford (1991). Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, IIth Ed., McGraw Hill Companies Inc., New York (2006).

[0076] In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. As used in this specification, the singular forms "a," "an" and "the" specifically also encompass the plural forms of the (15) terms to which they refer, unless the content clearly dictates otherwise.
Additionally, as used herein, unless specifically indicated otherwise, the word "or" is used in the "inclusive"
sense of "and/or" and not the "exclusive" sense of "either/or." The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about"
is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

[0077] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable that is inherently discrete, the variable can be equal to any integer value of the numerical range, including the end-points of the range.
Similarly, for a variable that is inherently continuous, the variable can be equal to any real value of the numerical range, including the end-points of the range. As an example, a variable that is described as having values between 0 and 2, can be 0, 1 or 2 for variables that are inherently discrete, and can be 0.0, 0.1, 0.01, 0.001, or any other real value for variables that are inherently continuous.

[0078] Reference is made hereinafter in detail to specific embodiments of the invention. While the invention will be described in conjunction with these specific embodiments, it will be understood that it is not intended to limit the invention to such specific embodiments. On the contrary, it is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other instances, well known process operations have not been described in detail, in order not to unnecessarily obscure the present invention.

[0079] Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.

(16) [0080] As used herein, "disease associated kinase" means those individual protein kinases or groups or families of kinases that are either directly causative of the disease or whose activation is associated with pathways that serve to exacerbate the symptoms of the disease in question.

[0081] The phrase "protein kinase modulation is beneficial to the health of the subject" refers to those instances wherein the kinase modulation (either up or down regulation) results in reducing, preventing, and/or reversing the symptoms of the disease or augments the activity of a secondary treatment modality.

[0082] The phrase "a cancer responsive to protein kinase modulation" refers to those instances where administration of the compounds of the invention either a) directly modulates a kinase in the cancer cell where that modulation results in an effect beneficial to the health of the subject (e.g., apoptosis or growth inhibition of the target cancer cell; b) modulates a secondary kinase wherein that modulation cascades or feeds into the modulation of a kinase that produces an effect beneficial to the health of the subject; or c) the target kinases modulated render the cancer cell more susceptible to secondary treatment modalities (e.g., chemotherapy or radiation therapy).

[0083] As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or compounds, but may also include additional features or compounds.

[0084] As used herein, the term "substituted 1,3-cyclopentadione compound"
refers to a compound selected from the group consisting of dihydro- (Rho) isoalpha acids; tetra-hydroisoalpha acids; hexa-hydroisoalpha acids; beta acids; xanthohumol; their individual analogs; and mixtures thereof. A substituted 1,3-cyclopentadione compound can be chemically synthesized de novo or extracted or derived from a natural source (e.g., hop or hop compounds).

(17) [0085] As used herein, the terms "derivatives" or a matter "derived" refer to a chemical substance related structurally to another substance and theoretically obtainable from it, i.e. a substance that can be made from another substance. Derivatives can include compounds obtained via a chemical reaction.

[0086] As used herein, "dihydro-isoalpha acid" or "Rho-isoalpha acid" refers to analogs of Rho-isoalpha acid- including cis and trans forms of the isohumulone (n-), isocohumulone (co-) and isadhumulone (ad-) analogs- as depicted in Table I or a mixture thereof. Rho-isoalpha acid, for example, refers to a mixture of one or more of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone.

[0087] As used herein, "tetrahydro-isoalpha acid" or "Meta-THc" refers to analogs of tetrahydro-isoalpha acid- including cis and trans forms of the isohumulone (n-), isocohumulone (co-) and isadhumulone (ad-) analogs- as depicted in Table 2 or a mixture thereof. Tetrahydro-isoalpha acid or Meta-THc, for example, refers to a mixture of one or more of tetrahydro-adhumulone, tetrahydro-isocohumulone, tetrahydro-isohumulone.

[0088] As used herein, "hexahydro-isoalpha acid" refers to analogs of hexahydro-isoalpha acid- including cis and trans forms of the isohumulone (n-), isocohumulone (co-) and isadhumulone (ad-) analogs- as depicted in Table 3 or a mixture thereof.
Hexahydro-isoalpha acid, for example, refers to a mixture of one or more of hexahydro-isohumulone, hexahydro-isocohumulone, hexahydro-adhumulone.

[0089] As used herein "beta acid" refers to any mixture of one or more of lupulone, colupulone, adlupulone, prelupulone, postlupuline or analogs thereof.

[0090] As used herein, "tetrahydro-isohumulone" shall further refer to the cis and trans forms of (+)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one, (-)-(4S,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-m ethyl butyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one respectively, or (n-) compounds shown in Table 2.

[0091] "Tetrahydro-isocohumulone", as used herein refers to the cis and trans forms of (+)-(4R,55)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en- l -one, (-)-(4S,5S)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-(18) methylpentanoyl)-2-(3-methylpropanoyl)cyclopent-2-en- I -one respectively, or (co-) compounds shown in Table 2.

100921 "Tetrahydro-adhumulone" shall be used herein to refer to the cis and trans forms of (+)-(4R,5S)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-l-one and (+)-(4R,5S)-3,4-dihydroxy-5-(3-methylbutyl)-4-(4-methylpentanoyl)-2-petanoylcyclopent-2-en-I-one respectively, or (ad-) compounds shown in Table 2.

10093] As used herein, "compounds" may be identified either by their chemical structure, chemical name, or common name. When the chemical structure and chemical or common name conflict, the chemical structure is determinative of the identity of the compound. The compounds described herein may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereomers. Accordingly, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated or identified compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof.
Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated or identified compounds. The compounds described also encompass isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into the compounds of the invention include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 180, 170, etc. Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may exist in multiple crystalline or amorphous forms. Also contemplated within the scope of the invention are congeners, analogs, hydrolysis products, metabolites and precursor or prodrugs of the compound. In general, unless otherwise indicated, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.

(19) [0094] Compounds according to the invention may be present as salts. In particular, pharmaceutically acceptable salts of the compounds are contemplated. A
"pharmaceutically acceptable salt" of the invention is a combination of a compound of the invention and either an acid or a base that forms a salt (such as, for example, the magnesium salt, denoted herein as "Mg" or "Mag") with the compound and is tolerated by a subject under therapeutic conditions. In general, a pharmaceutically acceptable salt of a compound of the invention will have a therapeutic index (the ratio of the lowest toxic dose to the lowest therapeutically effective dose) of 1 or greater. The person skilled in the art will recognize that the lowest therapeutically effective dose will vary from subject to subject and from indication to indication, and will thus adjust accordingly.

[0095] The compounds according to the invention are optionally formulated in a pharmaceutically acceptable vehicle with any of the well known pharmaceutically acceptable carriers, including diluents and excipients [see Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, Mack Publishing Co., Easton, PA 1990 and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, 1995]. While the type of pharmaceutically acceptable carrier/vehicle employed in generating the compositions of the invention will vary depending upon the mode of administration of the composition to a mammal, generally pharmaceutically acceptable carriers are physiologically inert and non-toxic. Formulations of compositions according to the invention may contain more than one type of compound of the invention), as well as any other pharmacologically active ingredient useful for the treatment of the symptom/condition being treated.

Table I

Rho dihydro-isoalpha acids Chemical Name Synonym Structure (4S,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4- o methylpent-3-en-l-yl]-2-(3- rho (6S) cis n methylbutanoyl)-5-(3-methylbut-2-en-1- iso-alpha acid H OH
HO"
yl)cyclopent-2-en-I -one (4S,5S)-3,4-dihydroxy-4-[(1 R)-hydroxy-4- 0 methylpent-3-en-l-yl]-2-(3- rho (6R) cis n methylbutanoyl)-5-(3-methylbut-2-en-1- iso-alpha acid HO.. OH
HO
yl)cyclopent-2-en-l-one (20) (4R,5S)-3,4-dihydroxy-4-[(l R)-hydroxy-4- 0 0 methylpent-3-en- l -yl]-2-(3- rho (6R) trans n methylbutanoyl)-5-(3-methylbut-2-en-I- iso-alpha acid Ho ' OH
yl)cyclopent-2-en-I -one (4R,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4- 0 0 methylpent-3-en-1-yl]-2-(3- rho (6S) trans n f~~
methYlhutanoY1)-5-(3-methYlout-2-en-1- iso-alpha acid HO H
Ho ' yl)cyclopent-2-en-I-one (4R,5R)-3,4-dihydroxy-4-[(1 R)-hydroxy-4- 0 O
methylpent-3-en-l-yl]-2-(3- rho (6R) cis rho methylbutanoyl)-5-(3-methylbut-2-en-1- n iso-alpha acid "O OH
~
yl)cyclopent-2-en-l-one HO

(4R,5R)-3,4-dihydroxy-4-[(1S)-hydroxy-4- 0 0 methylpent-3-en- I -yl]-2-(3- rho (6S) cis n methyl butanoyl)-5-(3-methyl but-2-en-1- iso-alpha acid "0 off HO' yl)eyclopent-2-en-l-one (4S,5R)-3,4-dihydroxy-4-[(IS)-hydroxy-4- O 0 methylpent-3-en-l-yl]-2-(3- (6S) trans rho n methyl butanoyl)-5-(3-methyl but-2-en-I- iso-alpha acid HO,' o"
yl)cyclopent-2-en-l-one (4S,5R)-3,4-dihydroxy-4-[(1R)-hydroxy-4- 0 0 methylpent-3-en-l-yl]-2-(3- rho (6R) trans n methyl butanoyl)-5-(3-methyl but-2-en-1- iso-alpha acid HO` 0H
yl)cyclopent-2-en-l-one (4S,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4-= O O
methylpent-3-en-l-yl]-5-(3-methylbut-2- rho (6S) cis co HO' "
en-I-Y1)-2-(2-methyl propanoY1)cYclopent- iso-alpha acid "a==
2-en-I-one (4S,5S)-3,4-dihydroxy-4-[(I R)-hydroxy-4- 0 O
methylpent-3-en-l-yl]-5-(3-methylbut-2- rho (6R) cis co en- I -I -2- 2-meth 1 ro ano 1 c clo ent- iso-al ha acid HO1 H
Y) ( YP p Y) Y p p "o 2-en-I-one (4R,5S)-3,4-dihydroxy-4- [(1 R)-hydroxy-4- O
methylpent-3-en- I -yl]-5-(3-methylbut-2- rho (6R) trans HO = QH
co iso-alpha en-I -yl)-2-(2-methylpropanoyl)cyclopent- HO
2-en-I-one acid (21) O O
(4R,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4- rho (6S) trans methylpent-3-en-l-yl]-5-(3-methylbut-2-en- I -1 -2- 2-meth 1 ro ano 1 c clo ent- co iso-alpha HO ; OH
Y) ( Yp p Y) Y p acid HO.1 2-en-I-one (4R,5R)-3,4-dihydroxy-4-[(1 R)-hydroxy-4- o methylpent-3-en-1-yl]-5-(3-methylbut-2- rho (6R) cis co en- I -1 -2-(2-m eth 1 ro ano 1 c clo ent- iso-al ha acid HO "
Y) YP p Y) Y p p HO
2-en-l-one Y

(4R,5R)-3,4-dihydroxy-4-[(1S)-hydroxy-4- O
methylpent-3-en-1-yl]-5-(3-methylbut-2- rho (6S) cis co en-I-Y1)-2-(2-methY1propanoY1)cYclopent- iso-alpha acid HoHO"'~ O"
2-en- I -one (4S,5R)-3,4-dihydroxy-4-[(I ~S')-hydroxy-4- O
methylpent-3-en-l-yl]-2-(2- rho - trans co isosoalpha HO= OH
methyl propanoyl)-5-(3-methylbut-2-en-1- acid HO"
yl)cyclopent-2-en-l-one (4S,5R)-3,4-dihydroxy-4-[(IR)-hydroxy-4- O
methylpent-3-en-l-yl]-5-(3-methylbut-2- rho trans en-I-yl)-2-(2-methylpropanoyl)cyclopent- co iso-alpha HO' off 2-en-I-one acid - 1 S)-hYdroxY-4- O O
(4S,~ 58 -3,4-dihYdroxY-4[( methylpent-3-en-I-yl]-2-(2- rho (6S) cis ad methylbutanoyl)-5-(3-methylbut-2-en-1- iso-alpha acid HO= O"
HO"
yl)cyc l opent-2-en- l -one (4S,5S)-3,4-dihydroxy-4-[(IR)-hydroxy-4-methylpent-3-en-1-yl]-2-(2- rho (6R) cis ad methylbutanoyl)-5-(3-methylbut-2-en-1- iso-alpha acid HO "
yl)cyclopent-2-en-I -one (4R,5S)-3,4-dihydroxy-4-[(IR)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- rho (6R) trans methylbutanoyl)-5-(3-methylbut-2-en-1- ad iso-alpha Ho OH
'~~, yl)cyclopent-2-en-l-one acid (4R,5S)-3,4-dihydroxy-4-[(IS)-hydroxy-4- O O
methylpent-3-en-l-yl]-2-(2- rho (6S) trans ad iso-alpha HO : OH
methylbutanoyl)-5-(3-methylbut-2-en-I- acid HO"
yl)cyclopent-2-en-l-one (22) (4R,5R).-3,4-dihydroxy-4-[(I R)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- rho (6R) cis ad methylbutanoyl)-5-(3-methylbut-2-en-1- iso-alpha acid HO = OH
"~Iy yl)cyclopent-2-en-l-one (4R,5R)-3,4-dihydroxy-4-[(1S)-hydroxy-4- o methylpent-3-en-l-yl]-2-(2- rho (6S) cis ad meth lbutano I -5- 3-meth lbut-2-en-1- iso-al ha acid NO ` "
Y Y) ( Y p H ,="
yl)cyclopent-2-en--l-one (4S,5R)-3,4-dihydroxy-4-[(IS)-hydroxy-4- rho (6S) trans O
methylpent-3-en- I -yl]-2-(2- ad iso-alpha HO" OH
methylbutanoyl)-5-(3-methylbut-2-en-1- acid yl)cyclopent-2-en- l -one (4S,5R)-3,4-dihydroxy-4-[(1R)-hydroxy-4-methylpent-3-en-l-yl]-2-(2- rho (6R) trans methylbutanoyl)-5-(3-methylbut-2-en-1- ad iso-alpha HO OH
yl)cyclopent-2-en-l-one acid Table 2 Tetrahydro-isoalpha acids Chemical Name Synonym Structure (4R,5S)-3,4-dihydroxy-2-(3- tetrahydro cis n methylbutanoyl)-5-(3-methylbutyl)-4-(4- HO" OH
methylpentanoyl)eyclopent-2-en-l-one iso-alpha acid (4S,5S)-3,4-dihydroxy-2-(.3-tetrahydro trans methylbutanoyl)-5-(3-methylbutyl)-4-(4- HO OH
methylpentanoyl)cyclopent-2-en-l-one n iso-alpha acid O ;_~ ~

O
(4S,5R)-3,4-dihydroxy-2-(3- tetrahydro cis n methylbutanoyl)-5-(3-methylbutyl)-4-(4- HO = off methylpentanoyl)eyclopent-2-en-l-one iso-alpha acid O O
(4R,5R)-3,4-dihydroxy-2-(3 methylbutanoyl)-5-(3-methylbutyl)-4-(4- tetrahydro trans HO"' OH
methylpentanoyl)cyclopent-2-en- I -one n iso-alpha acid O

(23) (4R,5S)-3,4-dihydroxy-5-(3-methylbutyl)-4-tetrahydro cis co (4-methylpentanoyl)-2-(3- Ho methylpropanoyl)cyclopent-2-en-l-one iso-alpha acid 0 N
(4S,5S)-3,4-dihydroxy-5-(3-methylbutyl)-4- tetrahydro trans (4-methylpentanoyl)-2-(3- "o j "
methylpropanoyl)cyclopent-2-en-l-one co iso-alpha acid (4S,5R)-3,4-dihydroxy-5-(3-methylbutyl)-4- 0 (4-methylpentanoyl)-2-(3- tetrahydro cis co "
methylpropanoyl)cyclopent-2-en- 1 -one iso-alpha acid H

(4R,5R)-3,4-dihydro xy-5-(3-methyl butyl)-4 4 meth I entano 1 2-3 tetrahydro trans ( y p y) (' co iso-alpha acid "~ "
methylpropanoyl)cyclopent-2-en-l-one (4R,5S)-3,4-dihydroxy-2-(2- tetrahydro cis ad methylbutanoyl)-5-(3-methylbutyl)-4-(4- iso-alpha acid "O,, H
methylpentanoyl)cyclopent-2-en- l -one a (4S,5,S)-3,4-dihydroxy-2-(2-A methylbutanoyl)-5-(3-methylbutyl)-4-(4- tetrahydro trans H. "
methylpentanoyl)cyclopent-2-en-l-one ad iso-alpha acid o (4S,5R)-3,4-dihydroxy-2-(2- tetrahydro cis ad methylbutanoyl)-5-(3-methylbutyl)-4-(4- " : "
methylpentanoyl)cyclopent-2-en-l-one iso-alpha acid (4R,5R)-3,4-dihydroxy-2-(2-methylbutanoyl)-5-(3-methylbutyl)-4-(4- tetrahydro trans HCI"
methyl pentanoyl)cyclopent-2-en-l-one ad iso-alpha acid "

Table 3 Hexahydro-isoalpha acids (24) Chemical Name Synonym Structure (4S,5S)-3,4-dihydroxy-4-[(1 S)-1-hydroxy- hexahydro (6S) rOH
4-methylpentyl]-2-(3-methylbutanoyl)-5- cis n iso-alpha Ho(3-methylbutyl)cyclopent-2-en-l -one acid HO"(4S,5S)-3,4-dihydroxy-4-[(1 R)-1-hydroxy- hexahydro (6R) 4-methylpentyl]-2-(3-methylbutanoyl)-5- cis n iso-alpha Ho" off (3-m ethyl butyl)cyclopent-2-en-l-one acid Ho (4R,5,S)-3,4-dihydroxy-4-[(1 R)-1-hydroxy- hexahydro (6R) 4-methylpentyl]-2-(3-methyl butanoyl)-5- trans n iso-alpha HO OH
(3-methylbutyl)cyclopent-2-en-l -one acid HO
(4R,S -3,4-dih YdroxY-4-[(IS)-1-hYdroxY- hexahydro (6S) O
4-methylpentyl]-2-(3-methylbutanoyl)-5- trans n iso-alpha HO OH
(3-methylbutyl)cyclopent-2-en- l -one acid HO"

(4R,5R)-3,4-dihydroxy-4-[(1R)-1-hydroxy- hexahydro (6R) O
4-methylpen tyl]-2-(3-methylbutanoyl)-5- cis n iso-alpha HO OH
(3-methylbutyl)cyclopent-2-en- l -one acid HO

(4R,5R)-.3,4-dihydroxy-4-[(1 S)-1-hydroxy- hexahydro (6S) 4-methylpentyl]-2-(3-methylbutanoyl)-5- cis n iso-alpha HO OH
(3-methylbutyl)cyclopent-2-en-l -one acid HO"

(4S,5R)-3,4-dihydroxy-4-[(1S)-1-hydroxy- hexahydro (6S) 4-methyl pentyl]-2-(3-methyl butanoyl)-5- trans n iso-alpha HO' OH
(3-methylbutyl)cyclopent-2-en-l -one acid HO"

(4S,5R)-3,4-dihydroxy-4-[(1R)-1-hydroxy- hexahydro (6R) O
4-methylpentyl]-2-(3-methylbutanoyl)-5- trans n iso-alpha HO'" OH
(3-m ethyl butyl)cyclopent-2-en-l-one acid HO

(4S,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4- O
methylpent-3-en-l-yl]-5-(3-methylbut-2- hexahydro (6S) cis co iso-alpha HO OH
en-1-Y1)-2-(2-methY1propanoY1)cYclopent- acid "G"
2-en- l -one (25) (4S,5S)-3,4-dihydroxy-4-[(1 R)-hydroxy-4- hexahydro (6R) =. 0 methylpent-3-en- l -yl]-5-(3-methylbut-2-cis co iso-alpha HO OH
en-I -yl)-2-(2-methylpropanoyl)cyclopent- acid 2-en- I -one (4R,5S)-3,4-dihydroxy-4-[(1R)-hydroxy-4- hexahydro (6R) ~,= 0 0 methylpent-3-en- l -yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)cyclopent- trans coiso- HO. OH
2-en-l-one alpha acid HO

4R 5 3 4-dih drox 4- 1 h drox 4- a methylpent-3-en-1-yl]-5-(3-methylbut-2- hexahydro (6,S) en- I -1 -2- 2-meth 1 ro ano 1 c clo ent- trans co iso- Hp kH
Y) ( Y p p Y) Y p alpha acid 2-en- I -one 4R 5R 3 4-dih drox 4- 1 R h drox 4- O
( ) Y Y [( )- Y Y hexahydro (6R) methylpent-3-en-1-yl]-5-(3-methylbut-2-en-I -yl)-2-(2-methylpropanoyl)cyclopent- cis co iso-alpha H~ ".- OH
acid 2-en- l -one 0"~
(4R,5R)-3,4-dihydroxy-4-[(IS)-hydroxy-4- hexahydro (68) O
methylpent-3-en-1-yl]-5-(3-methylbut-2-en-l-yl)-2-(2-methylpropanoyl)eyclopent- cis co iso-alpha HO . OH
acid HO
2-en-l-one (4S,5R)-3,4-dihydroxy-4-[(1S)-hydroxy-4- o methylpent-3-en-I-yl]-2-(2- hexahydo (6S) methylpropanoyl)-5-(3-methylbut-2-en-1- trans criso- HO" off yl)cyclopent-2-en-I-one alpha acid (4S,5R)-3,4-dihydroxy-4- [(I R)-hydroxy-4- o methylpent-3-en-l-yl]-5-(3-methylbut-2- hexahydro en-l-yl)-2-(2-methylpropanoyl)cyclopent- trans pcoiso- (6R) Ho ' off 2-en-l-one alpha acid (4S,5S)-3,4-dihydroxy-4-[(1S)-hydroxy-4- hexahydro (6S) 0 methylpent-3-en-1-yl]-2-(2-cis ad iso-alpha HO' OH
methylbutanoyl)-5-(3-methylbut-2-en-I- acid HO'"
yl)cyclopent-2-en- l -one (4S,5S)-3,4-dihydroxy-4-[(I R)-hydroxy-4- O
methylpent-3-en-l-yl]-2-(2- hexahydro (6R) ~.,.
methylbutanoyl)-5-(3-methylbut-2-en-I- cis ad iso-alpha HO , OH
yl)cyclopent-2-en-l-one acid (26) (4R,5S)-3,4-dihydroxy-4- [(1R)-hydroxy-4-methyl pent-.3-en- I -yl]-2-(2- hexahydro (6R) ~.=~x~
methylbutanoyl)-5-(3-methylbut-2-en-1- trans ad iso- Ho = OH
yl)eyclopent-2-en-l-one alpha acid (4R,5S)-3,4-dihydroxy-4-[(IS)-hydroxy-4-methylpent-3-en-1-yl]-2-(2- hexahydro (6S) =, ~.H
trans ad iso- H_ methylbutanoyl)-5-(3-methylbut-2-en-1- alpha acid H ==
yl)eyclopent-2-en-l-one (4R,5R)-3,4-dihydroxy-4-[(1R)-hydroxy-4- hexahydro (6R) 0 methylpent-3-en- l -yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-1- cis ad iso-alpha HO OH
yl)cyclopent-2-en-l-one acid `I
(4R,5R)-3,4-dihydroxy-4-[(1S)-hydroxy-4-methylpent-3-en-1-yl]-2-(2- hexahydro (6S) methylbutanoyl)-5-(3-methylbut-2-en-I- cis ad iso-alpha HO OH
yl)cyclopent-2-en-1 -one acid (4S,5R)-3,4-dihydroxy-4-[(IS)-hydroxy-4- hexahydro (6S) methylpent-3-en-I -yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-1- trans ad iso- Ho OH
yl)cyclopent-2-en-l-one alpha acid (4S,5R)-3,4-dihydroxy-4-[(IR)-hydroxy-4- hexahydro (6R) methylpent-3-en- l -yl]-2-(2-methylbutanoyl)-5-(3-methylbut-2-en-I- trans ad iso- HO H
yl)cyclopent-2-en-l-one alpha acid 100961 The term "modulate" or "modulation" is used herein to mean the up or down regulation of expression or activity of the enzyme by a compound, ingredient, etc., to which it refers.

[00971 As used herein, the term "protein kinase" represent transferase class enzymes that are able to transfer a phosphate group from a donor molecule to an amino acid residue of a protein. See Kostich, M., et al., Human Members of the Eukaryotic Protein Kinase Family, Genome Biology 3(9):research0043.1-0043.12, 2002 herein incorporated by reference in its entirety, for a detailed discussion of protein kinases and family/group nomenclature.

(27) [00981 Representative, non-limiting examples of kinases include Abl, Abl(T315I), ALK, ALK4, AMPK, Arg, Arg, ARKS, ASK!, Aurora-A, Ax], Blk, Bmx, BRK, BrSKI, BrSK2, BTK, CaMKI, CaMKII, CaMKIV, CDK I /cyclinB, CDK2/cyclinA, CDK2/cyclinE, CDK.3/cyclinE, CDK5/p25, CDK5/p35, CDK6/cyclinD3, CDK7/cyclinH/MAT1, CDK9/cyclin Ti, CHKI, CHK2, CK1(y), CK16, CK2, CK2a2, cKit(D816V), cKit, c-RAF, CSK, cSRC, DAPKI, DAPK2, DDR2, DMPK, DRAKI, DYRK2, EGFR, EGFR(L858R), EGFR(L861Q), EphAl, EphA2, EphA3, EphA4, EphA5, EphA7, EphA8, EphBl, EphB2, EphB3, EphB4, ErbB4, Fer, Fes, FGFRI, FGFR2, FGFR3, FGFR4, Fgr, Fitl, Flt3(D835Y), Flt3, Flt4, Fms, Fyn, GSK3B, GSK3a, Hck, HIPK1, HIPK2, HIPK3, IGF-IR, IKKB, IKKa, IR, IRAK I , IRAK4, IRR, ITK , JAK2, JAK3, JNK 1 a 1, JNK2a2, JNK3, KDR, Lck, LIMKI, LKBI, LOK, Lyn, Lyn, MAPKI, MAPK2, MAPK2, MAPKAP-K2, MAPKAP-K3, MARK!, MEKI, MELK, Met, MINK, MKK4, MKK6, MKK7B, MLCK, MLKI, Mnk2, MRCKB, MRCKa, MSKI, MSK2, MSSK1, MSTI, MST2, MST3, MuSK, NEK2, NEK3, NEK6, NEK7, NLK, p70S6K, PAK2, PAK3, PAK4, PAK6, PAR-113a, PDGFRB, PDGFRa, PDKI, P13K, beta, P13K delta, P13K gamma, Pim-1, Pim-2, PKA(b), PKA, PKBB, PK.Ba, PKBy, PKC , PKCBI, PKCBII, PKCa, PKC7, PKC6, PKCc, PKCc, PKCq, PKCO, PKCt, PKD2, PKG I B, PKG 1 a, Plk3, PRAK, PRK2, PrKX, PTK5, Pyk2, Ret, RIPK2, ROCK-I, ROCK-II, ROCK-II, Ron, Ros, Rse, Rskl, Rskl, Rsk2, Rsk3, SAPK2a, SAPK2a(T106M), SAPK2b, SAPK.3, SAPK4, SGK, SGK2, SGK3, SIK, Snk, SRPK1, SRPK2, STK33, Syk, TAK1, TBKI, Tie2, TrkA, TrkB, TSSK1, TSSK2, WNK.2, WNK3, Yes, ZAP-70, ZIPK. In some embodiments, the kinases may be ALK, Aurora-A, Ax], CDK9/cyclin Ti, DAPKI, DAPK2, Fer, FGFR4, GSK3B, GSK3a, Hck, JNK2a2, MSK2, p70S6K, PAK3, P13K delta, P13K gamma, PKA, PKBB, PKBa, Rse, Rsk2, Syk, TrkA, and TSSK1. In yet other embodiments the kinase is selected from the group consisting of ABL, AKT, AURORA, CDK, DBF2/20, EGFR, EPH/ELK/ECK, ERK/MAPKFGFR, GSK3, IKKB, INSR, JAK DOM 1/2, MARK/PRKAA, MEK/STE7, MEKK/STE 11, MLK, mTOR, PAK/STE20, PDGFR, P13K, PKC, POLO, SRC, TEC/ATK, and ZAP/SYK.

10099] The methods and compositions of the present invention are intended for use with any mammal that may experience the benefits of the methods of the invention.
Foremost among such mammals are humans, although the invention is not intended to be so limited, and is applicable to veterinary uses. Thus, in accordance with the invention, "mammals" or "mammal in need" include humans as well as non-human mammals, particularly domesticated animals including, without limitation, cats, dogs, and horses.

(28) [00100] As used herein "cancer" refers to any of various benign or malignant neoplasms characterized by the proliferation of anaplastic cells that, if malignant, tend to invade surrounding tissue and metastasize to new body sites. Representative, non-limiting examples of cancers considered within the scope of this invention include brain, breast, colon, kidney, leukemia, liver, lung, and prostate cancers. Non-limiting examples of cancer associated protein kinases considered within the scope of this invention include ABL, AKT, AMPK, Aurora, BRK, CDK, CHK, EGFR, ERB, FGFR, IGFR, KIT, MAPK, mTOR, PDGFR, P13K, PKC, and SRC.

1001011 The term "angiogenesis" refers to the growth of new blood vessels-an important natural process occurring in the body. In many serious diseases states, the body loses control over angiogenesis, a condition sometime known as pathological angiogenesis.
Angiogenesis-dependent diseases result when new blood vessels grow excessively.
Examples of angiogenesis-related disorders include chronic inflammation (e.g., rheutatoid arthritis or Crohn's disease), diabetes (e.g., diabetic retinopathy), macular degeneration, psoriasis, endometriosis, and ocular disorders and cancer. "Ocular disorders"
(e.g., corneal or retinal neovascularization), refers to those disturbances in the structure or function of the eye resulting from developmental abnormality, disease, injury, age or toxin.
Non-limiting examples of ocular disorders considered within the scope of the present invention include retinopathy, macular degeneration or diabetic retinopathy. Ocular disorder associated kinases include, without limitation, AMPK, Aurora, EPH, ERB, ERK, FMS, IGFR, MEK, PDGFR, P13K, PKC, SRC, and VEGFR.

[001021 Any condition or disorder that is associated with or that results from pathological angiogenesis, or that is facilitated by neovascularization (e.g., a tumor that is dependent upon neovascularization), is amenable to treatment with a substituted 1,3-cyclopentadione compound.

[00103] Conditions and disorders amenable to treatment include, but are not limited to, cancer; proliferative retinopathies such as diabetic retinopathy, age-related maculopathy, retrolental fibroplasia; excessive fibrovascular proliferation as seen with chronic arthritis;
psoriasis; and vascular malformations such as hemangiomas, and the like.

[00104] The compositions and methods of the present invention are useful in the treatment of both primary and metastatic solid tumors, including carcinomas, sarcomas, (29) leukemias, and lymphomas. Of interest is the treatment of tumors occurring at a site of angiogenesis. Thus, the methods are useful in the treatment of any neoplasm, including, but not limited to, carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract, (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas). The instant methods are also useful for treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e, chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas). In addition, the instant methods are useful for reducing metastases from the tumors described above either when used alone or in combination with radiotherapy, other chemotherapeutic and/or anti-angiogenesis agents.

[00105] As used herein, by "treating" is meant reducing, preventing, and/or reversing the symptoms in the individual to which a compound of the invention has been administered, as compared to the symptoms of an individual not being treated according to the invention. A practitioner will appreciate that the compounds, compositions, and methods described herein are to be used in concomitance with continuous clinical evaluations by a skilled practitioner (physician or veterinarian) to determine subsequent therapy. Hence, following treatment the practitioners will evaluate any improvement in the treatment of the pulmonary inflammation according to standard methodologies.
Such evaluation will aid and inform in evaluating whether to increase, reduce or continue a particular treatment dose, mode of administration, etc.

[00106] It will be understood that the subject to which a compound of the invention is administered need not suffer from a specific traumatic state. Indeed, the compounds of the invention may be administered prophylactically, prior to any development of symptoms.
The term "therapeutic," "therapeutically," and permutations of these terms are used to (30) encompass therapeutic, palliative as well as prophylactic uses. Hence, as used herein, by "treating or alleviating the symptoms" is meant reducing, preventing, and/or reversing the symptoms of the individual to which a compound of the invention has been administered, as compared to the symptoms of an individual receiving no such administration.

[00107] The term "pharmaceutically acceptable" is used in the sense of being compatible with the other ingredients of the compositions and not deleterious to the recipient thereof.

[00108] The term "therapeutically effective amount" is used to denote treatments at dosages effective to achieve the therapeutic result sought. Furthermore, one of skill will appreciate that the therapeutically effective amount of the compound of the invention may be lowered or increased by fine tuning and/or by administering more than one compound of the invention, or by administering a compound of the invention with another compound.
See, for example, Meiner, C.L., "Clinical Trials: Design, Conduct, and Analysis,"
Monographs in Epidemiology and Biostatistics, Vol. 8 Oxford University Press, USA
(1986). The invention therefore provides a method to tailor the administration/treatment to the particular exigencies specific to a given mammal. As illustrated in the following examples, therapeutically effective amounts may be easily determined for example empirically by starting at relatively low amounts and by step-wise increments with concurrent evaluation of beneficial effect.

[00109] It will be appreciated by those of skill in the art that the number of administrations of the compounds according to the invention will vary from patient to patient based on the particular medical status of that patient at any given time including other clinical factors such as age, weight and condition of the mammal and the route of administration chosen.

[00110] As used herein, "symptom" denotes any sensation or change in bodily function that is experienced by a patient and is associated with a particular disease, i.e., anything that accompanies "X" and is regarded as an indication of "Y"s existence. It is recognized and understood that symptoms will vary from disease to disease or condition to condition. By way of non-limiting examples, symptoms associated with autoimmune disorders include fatigue, dizziness, malaise, increase in size of an organ or tissue (for example, thyroid enlargement in Grave's Disease), or destruction of an organ or tissue (31) resulting in decreased functioning of an organ or tissue (for example, the islet cells of the pancreas are destroyed in diabetes).

[001111 "Inflammation" or "inflammatory condition" as used herein refers to a local response to cellular injury that is marked by capillary dilatation, leukocytic infiltration, redness, heat, pain, swelling, and often loss of function and that serves as a mechanism initiating the elimination of noxious agents and of damaged tissue.
Representative symptoms of inflammation or an inflammatory condition include, if confined to a joint, redness, swollen joint that's warm to touch, joint pain and stiffness, and loss of joint function. Systemic inflammatory responses can produce "flu-like" symptoms, such as, for instance, fever, chills, fatigue/loss of energy, headaches, loss of appetite, and muscle stiffness.

[00112] A first aspect of the invention discloses methods to treat a cancer responsive to protein kinase modulation in a mammal in need, where the method comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound. In some embodiments of this invention, the substituted 1,3-cyclopentadione compound is selected from the group consisting of dihydro-(Rho) isoalpha acids; tetra-hydroisoalpha acids; hexa-hydroisoalpha acids; beta acids; their individual analogs; and mixtures thereof. In other embodiments of this aspect, the substituted 1,3-cyclopentadione compound is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

[00113] In other embodiments of this aspect, the protein kinase modulated is selected from the group consisting of Abl(T31 S1), Aurora-A, Bmx, BTK, CaMKI, CaMKI6, CDK2/cyclinA, CDK3/cyclinE, CDK9/cyclin TI, CKI(y), CKlyl, CKIy2, CKIy3, CK18, cSRC, DAPK1, DAPK2, DRAK1, EphA2, EphA8, Fer, FGFR2, FGFR3, Fgr, Flt4, JNK3, P13K, Pim-1, Pim-2, PKA, PKA(b), PKBB, PKBa, PKBy, PRAK, PrKX, Ron, Rskl, Rsk2, SGK2, Syk, Tie2, TrkA, and TrkB.

[00114] In still other embodiments, the cancer responsive to kinase modulation is selected from the group consisting of bladder, breast, cervical, colon, lung, lymphoma, melanoma, prostate, thyroid, and uterine cancer. Other cancer types treatable by the methods of the present invention are described above.

(32) 100115] A second aspect of the invention describes methods to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need. The method comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound. In some embodiments of this invention, the substituted 1,3-cyclopentadione compound is selected from the group consisting of dihydro-(Rho) isoalpha acids; tetra-hydroisoalpha acids; hexa-hydroisoalpha acids; beta acids; their individual analogs; and mixtures thereof. In other embodiments of this aspect, the substituted 1,3-cyclopentadione compound is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

[001161 In one embodiment of this aspect, the protein kinases modulated are those associated with the regulation of angiogenesis including, without limitation, ATK, MAPK, PRAK, P13K, PKC, GSK, FGFR, BTK, PDK, SYK, MSK and IKKb.

[00117] In another embodiment of this second aspect, the method generally involves administering to a mammal a substituted 1,3-cyclopentadione compound in an amount effective to reduce angiogenesis. An effective amount for reduction of angiogenesis, in vivo, is any amount that reduces angiogenesis between at least about 5% to 100% as compared to an untreated (e.g., a placebo-treated) control.

[00118] Whether angiogenesis is reduced can be determined using any known method. Methods of determining an effect of an agent on angiogenesis are known in the art and include, but are not limited to, inhibition of neovascularization into implants impregnated with an angiogenic factor; inhibition of blood vessel growth in the cornea or anterior eye chamber; inhibition of endothelial cell proliferation, migration or tube formation in vitro; the chick chorioallantoic membrane assay; the hamster cheek pouch assay; the polyvinyl alcohol sponge disk assay. Such assays are well known in the art and have been described in numerous publications, including, e.g., Auerbach et al.
(Pharmacol.
Ther. 51(1):1-11(1991)), and references cited therein.

[00119] In another embodiment that relates to both first and second aspects of the present invention, the invention further provides methods for treating a condition or disorder associated with or resulting from pathological angiogenesis. In the context of cancer therapy, a reduction in angiogenesis according to the methods of the invention effects a reduction in tumor size; and a reduction in tumor metastasis. Whether a reduction in tumor (33) size is achieved can be determined, e.g., by measuring the size of the tumor, using standard imaging techniques. Whether metastasis is reduced can be determined using any known method. Methods to assess the effect of an agent on tumor size are well known, and include imaging techniques such as computerized tomography and magnetic resonance imaging. In accordance to this embodiment, an effective amount of a substituted 1,3-cyclopentadione compound is administered to a mammal in need thereof, which causes a reduction of the tumor size, in vivo, by at least about 5% or more, when compared to an untreated (e.g., a placebo-treated) control.

[00120] A third aspect of the invention describes methods to modulate inflammation associated with cancer or angiogenesis. The method comprises administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.
In one embodiment, an effective amount of a substituted 1,3-cyclopentadione compound is administered to a mammal in need thereof, which results in reduction of inflammation or inflammation associated symptoms such as pain, by at least about 10% or more, when compared to an untreated (e.g., a placebo-treated) control. Whether a reduction in inflammation is achieved can be determined, e.g., by clinical observation or by measuring the modulation or inhibition of PGE2, nitric oxide or various DNA or protein markers of inflammation.

[00121] A fourth aspect of the invention describes compositions to treat or inhibit angiogenesis, cancers and/or their associated inflammatory pathways responsive or susceptible to protein kinase modulation, in a mammal in need thereof. The compositions comprise a therapeutically effective amount of a substituted 1,3-cyclopentadione compound; wherein the therapeutically effective amount modulates an angiogenic associated protein kinase, a cancer associated protein kinase and/or an inflammation associated protein kinase. In some embodiments of this aspect of the invention, the substituted 1,3-cyclopentadione compound is selected from the group consisting of dihydro- (Rho) isoalpha acids; tetra-hydroisoalpha acids; hexa-hydroisoalpha acids; beta acids; their individual analogs; and mixtures thereof. In other embodiments of this aspect, the substituted 1,3-cyclopentadione compound is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

[00122] Compositions used in the methods of this aspect may further comprise one or more members selected from the group consisting of antioxidants, vitamins, minerals, (34) proteins, fats, and carbohydrates, or a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

1001231 In other embodiment of this fourth aspect, the compositions further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

1001241 To practice the method of the present invention, the above-described compounds and compositions can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, vaginally or via an implanted reservoir.

[001251 A composition for oral administration can be any orally acceptable dosage form including, but not limited to, capsules, tablets, powder, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.

[001261 The carrier in the therapeutic composition must be `acceptable' in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated. For example, solubilizing agents such as cyclodextrins, which form specific, more soluble complexes with the 1,3-cyclopentadione compounds, or one or more solubilizing agents, can be utilized as pharmaceutical excipients for delivery of the fused bicyclic heterocyclic compounds.
Examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10.

[001271 The dose of a substituted 1,3-cyclopentadione compound of the invention administered to a subject, particularly a human, in the context of the present invention (35) should be sufficient to effect a therapeutic reduction in angiogenesis, tumor size/progression or inflammation in the subject over a reasonable time frame. The dose will be determined by, among other considerations, the potency of the particular substituted 1,3-cyclopentadione compound employed and the condition of the subject, as well as the body weight of the subject to be treated.

[00128] In determining the effective amount of a substituted 1,3-cyclopentadione compound in the reduction of, for example, angiogenesis, the route of administration, the kinetics of the release system (e.g., pill, gel or other matrix), and the potency of the substituted 1,3-cyclopentadione compound are considered so as to achieve the desired anti-angiogenic effect with minimal adverse side effects. The substituted 1,3-cyclopentadione compound will typically be administered to the subject being treated for a time period ranging from a day to a few weeks, consistent with the clinical condition of the treated subject.

[00129] As will be readily apparent to the ordinarily skilled artisan, the dosage is adjusted for substituted 1,3-cyclopentadione compounds according to their potency and/or efficacy relative to a standard. See, for example, Example 17. A dose may be in the range of about 0.01 mg to 1000 mg, or about 0.1 to 100 mg, or about 0.5 to 50 mg, or about I to 25 mg, given 1 to 20 times daily, and can be up to a total daily dose of about 0.1 mg to 10000 mg. If applied topically, for the purpose of a systemic effect, the patch or cream is designed to provide for systemic delivery of a dose in the range of about 0.01 mg to 1000 mg, or about 0.1 to 100 mg, or about 0.5 to 50 mg, or about I to 25 mg. If the purpose of the topical formulation (e.g., cream) is to provide a local anti-angiogenic effect, the dose is generally in the range of about 0.001 mg to 10 mg or about 0.01 to 10 mg, or about 0.1 to mg.

[00130] Regardless of the route of administration, the dose of substituted 1,3-cyclopentadione compound can be administered over any appropriate time period, e.g., over the course of 1 to 24 hours, over one to several days, etc. Furthermore, multiple doses can be administered over a selected time period. A suitable dose can be administered in suitable subdoses per day, particularly in a prophylactic regimen. The precise treatment level will be dependent upon the response of the subject being treated.

(36) [00131] In some embodiments relating to all aspects of the present invention, a substituted 1,3-cyclopentadione compound is administered alone or in a combination therapy with one or more other substituted 1,3-cyclopentadiones and/or other therapeutic agents, including an inhibitor of angiogenesis; and optionally a cancer chemotherapeutic agent.

[00132] In one embodiment, an effective amount a composition containing of one or more of individual (n), (co) or (ad) analogs of a substituted 1,3-cyclopentadione compound are administered to a mammal in need thereof as the only substituted 1,3-cyclopentadione compound(s) in the composition. The (n), (co) and (ad) analogs of a substituted 1,3-cyclopentadione compound are depicted in Tables 1-3. For example, a composition may include only TH5 (an (n) analog) as the only substituted 1,3-cyclopentadione compound in the composition. Another composition may include cis-TH5 and trans-TH7 (both are (n) analogs of tetrahydro-isoalpha acid) as the only substituted 1,3-cyclopentadione compounds in the composition. Another composition may include TH1 and TH2 (both as (co) analogs of tetrahydro-isoalpha acid) as the only substituted 1,3-cyclopentadione compounds in the composition. Another composition may include TH4 and TH6 (both as (ad) analogs of tetrahydro-isoalpha acid) as the only substituted 1,3-cyclopentadione compounds in the composition. Figure 2 depicts the chemical structures of TH compounds.

[00133] In another embodiment, an effective amount a composition containing one or more (n) analogs of a substituted 1,3-cyclopentadione compound is administered in combination with one or more (ad) analogs of a substituted 1,3-cyclopentadione compound in accordance with the methods of the invention. For example, a composition may include TH4 (an (ad) analog) and TH5 (an (n) analog). It has been shown that TH4 and TH5 at 100 pg/mL almost completely inhibit BMX kinase. Other compositions may contain TH5 and TH6; TH7 and TH4; and TH7 and TH6.

[00134] The advantage of using one or more analogs of a substituted 1,3-cyclopentadione compound in a composition is that higher doses of specific analogs can be used without toxic side effects of using those with less activity on a given target. Another advantage is achieving selectivity or specificity. For example, the tetrahydro-isocohumulone (i.e., THI) is less preferred in both animal and in vitro inflammation models. However, THI and TH2 are more specific and are preferred in the treatment of certain cancers due to having a higher Gini coefficient (see Figures 23-24).
Gini coefficient (37) is a measure of selectivity of kinase inhibitors against a panel of kinases (Craczyk P., J Med Chem. Nov. 15:50(23)5773-9 (2007)). Briefly, nonselective inhibitors are characterized by Gini coeffients close to zero while highly selective compounds exhibit Gini coefficients close to 1. It has further been observed that while TH4 and TH5 are more active at 100 pg/ml in inhibiting BMX (inhibit it almost completely), THI, TH2 have about 50% of the activity in comparison. This same type of selectivity is observed for TRK.B, PrKX, CKI
delta, BTK, JAK3, R.SK.I, CDK2/cyclinE, EGFR(L858R), NEK, PKB beta, Arg, Src(l-530), TrkA, Rsk4. Further, as shown in Figure 23, although TH7's Gini coefficient profile is in the middle, TH7 has been observed to act more similar to TH4 and TH5 over the dose range. The Gini coefficients of THI-7 have also been compared with the Gini coefficients of compounds known to function as anti-cancer or anti-angiogeneis drugs (Figure 24). The data also indicate that THI-7 are individually more selective protein kinse inhibitors than THIAA which is a misture of same. Another advantage of using a composition of two or more analogs of a substituted 1,3-cyclopentadione compound can be modulation of more kinase targets than when only a single analog is used.

1001351 Accordingly, in some embodiments relating to all aspects of the present invention the following exemplary combinations of analogs of a substituted 1,3-cyclopentadione compound are contemplated, which are expected to have the benefits specified in the parentheses that follows each combination: (i) tetrahydro-isohumulone cis and trans: TH5 + TH7 (benefit: more targets); (ii) tetrahydro-isoadhumulone cis and trans:
TH4+TH6 (benefit: more targets); (iii) (n) and (ad) families: TH5+TH4;
TH5+TH6;
TH7+TH4; TH7+TH6 (benefit: more targets); (iv) tetrahydroiso-cohumulone cis and trans:
THI + TH2 (benefit: higher gini); and (v) (n) and (co) families THI+TH5;
TH2+TH5;
THI+TH7; TH2+TH7 (benefit: more targets).

[001361 With regard to other combination therapies, a substituted 1,3-cyclopentadione compound of the invention can be used in combination with suitable chemotherapeutic agents including, but are not limited to, the alkylating agents, e.g.
Cisplatin, Cyclophosphamide, Altretamine; the DNA strand-breakage agents, such as Bleomycin; DNA topoisomerase II inhibitors, including intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, and Mitoxantrone; the nonintercalating topoisomerase II inhibitors such as, Etoposide and Teniposide; the DNA
minor groove binder Plicamycin; alkylating agents, including nitrogen mustards such as (38) Chlorambucil, Cyclophosphamide, Isofamide, Mechlorethamine, Melphalan, Uracil mustard; aziridines such as Thiotepa; methanesulfonate esters such as Busulfan; nitroso ureas, such as Carmustine, Lomustine, Streptozocin; platinum complexes, such as Cisplatin, Carboplatin; bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine; antimetabolites, including folate antagonists such as Methotrexate and trimetrexate; pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine; Floxuridine purine antagonists including Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin; sugar modified analogs include Cyctrabine, Fludarabine; ribonucleotide reductase inhibitors including hydroxyurea;
Tubulin interactive agents including Vincristine Vinblastine, and Paclitaxel; adrenal corticosteroids such as Prednisone, Dexamethasone, Methylprednisolone, and Prodnisolone; hormonal blocking agents including estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbesterol, Chlorotrianisene and Idenestrol; progestins such as Hydroxyprogesterone caproate, Medroxyprogesterone, and Megestrol; androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbesterol, Chlorotrianisene and Idenestrol; progestins such as Hydroxyprogesterone caproate, Medroxyprogesterone, and Megestrol; androgens such as testosterone, testosterone propionate;
fluoxymesterone, methyl testosterone; and the like.

1001371 The substituted 1,3-cyclopentadione compound may be administered with other anti-angiogenic agents. Furthermore, a substituted 1,3-cyclopentadione compound of the invention can be used in combination with anti-angiogenic agents including, but are not limited to, angiostatic steroids such as heparin derivatives and glucocorticosteroids;
thrombospondin; cytokines such as IL-12; fumagillin and synthetic derivatives thereof, such as AGM 12470; interferon-a; endostatin; soluble growth factor receptors;
neutralizing monoclonal antibodies directed against growth factors; and the like.

[001381 The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein.

EXAMPLES

(39) Example I

Effects of Meta-THc on protein kinases [00139] As stated above, kinases represent transferase class enzymes that transfer a phosphate group from a donor molecule (usually ATP) to an amino acid residue of a protein (usually threonine, serine or tyrosine). Kinases are used in signal transduction for the regulation of enzymes, i.e., they can inhibit or activate an enzyme, such as an enzyme involved in cholesterol biosynthesis, amino acid transformation, or glycogen turnover.
While most kinases are specialized to a single kind of amino acid residue for phosphorylation, some kinases exhibit dual activity in that they can phosphorylate two different kinds of amino acids.

[00140] Methods - The dose responsiveness for kinase inhibition (reported as a percent of control) of a Meta-THc preparation was tested at approximately 1, 10, 25, and 50 ug/ml on 86 selected kinases as presented in Table 1 below. The inhibitory effect of the present method on human kinase activity was tested in the KinaseProfilerTM
Assay (Upstate Cell Signaling Solutions, Upstate USA, Inc., Charlottesville, VA., USA). The assay protocols for specific kinases are summarized at www.upstate.com/img/pdf/kp protocols full.pdf, incorporated herein by reference thereto.
[00141] Results - Meta-THc displayed a dose dependent inhibition of kinase activity for many of the kinases examined with inhibition of FGFR2 of 7%, 16%, 77%, and 91% at 1, 5, 25, and 50 ig/ml, respectively. Similar results were observed for FGFR3 (0%, 6%, 61%, and 84%) and TrkA (24%, 45%, 93%, and 94%) at 1, 5, 25, and 50 g/ml respectively.

[00142] The inhibitory effects of Meta-THc on the kinases tested are shown in Table 4 below.

Table 4 Dose response effect (as % of Control) of Meta-THc on selected protein kinases 1Kinase 1 5 25 50 ug/ml u /ml u /ml u /ml Abl(T3151) 104 95 68 10 (40) Aurora-A 102 86 50 5 Bmx 110 105 57 30 CaMKI 163 132 65 16 CaMK.IIt3 106 102 90 71 CaMKIIy 99 101 87 81 CaMKII8 99 103 80 76 CaMKIV 99 117 120 126 CaMKI6 91 95 61 43 CDK 1 /cyclinB 82 101 77 66 CDK2/cyclinA 118 113 87 50 CDK2/cyclinE 87 79 73 57 CDK3/cyclinE 113 111 105 32 CDK5/p25 102 100 85 54 CDK5/p35 109 106 89 80 CDK6/cyclinD3 114 113 112 70 CDK9/cyclin TI 106 93 66 36 CKI(y) 101 101 55 CKlyl 101 100 42 43 CKly2 94 85 33 48 CK1y3 99 91 23 18 CK 1 c3 109 97 65 42 cKit(D816H) 113 113 69 75 cSRC 105 103 91 17 EphA2 110 112 85 31 EphA8 110 110 83 43 EphBl 153 177 196 53 ErbB4 124 125 75 56 Fer 85 41 24 12 Fes 112 134 116 57 FGFRI(V561M) 97 106 91 92 Fgr 121 120 110 47 Flt4 126 119 85 31 IK.K.a 139 140 140 102 JNKIa1 71 118 118 107 JNK2a2 94 97 98 101 (41) Lek 97 105 125 88 Pim-1 103 100 44 44 Pim-2 103 109 83 22 PKA(b) 104 77 32 0 PKBa 103 101 49 50 PKC t 90 90 93 87 PKCa 110 111 112 102 PKCy 86 95 77 62 PKC( 93 100 107 103 PKCq 82 99 103 90 PKCt 77 90 93 134 PrKX 92 76 32 38 Ron 120 110 97 42 Ros 105 105 94 93 Rskl 101 87 48 31 Rsk2 100 85 40 14 Syk 99 93 55 17 Tie2 109 115 100 32 TrkA 107 65 30 15 TrkB 97 96 72 21 Example 2 Isolation and identification of Meta-THc components [001431 High speed counter current separation was conducted to isolated and identify the components of a Meta-THc sample. A modified hops extract containing tetrahydro iso-alpha acids was obtained from Hopsteiner (Yakima, WA) as a pure solid. This material was (42) partitioned between dilute H2SO4 (aq) pH=2.0 and hexanes and extracted several times with hexanes. The hexanes were collected, dried (NaSO4) and filtered to remove the NaSO4 and concentrated in vacuo to yield a waxy solid.

1001441 High Speed Counter Current (HSCCC) apparatus - Separations were performed on a Pharma-Tech Research Corporation CCC-1000 model counter-current chromatograph with semi-preparative centrifuge coils (total volume 325 mL) installed.
Samples were injected into the system using a Rheodyne manual injector with a 10.0 mL
sample loop. A Shimadzu LC-20AT Pump (switchable between four solvents) was used in conjunction with a Shimadzu CBM-20A system controller. Flow from the Pharma-Tech CCC-1000 went through a Shimadzu SPD-IOAVvp UV-VIS detector (monitoring at 254 nm) and to a Shimadzu FRC-IOA fraction collector with a large-scale fractionation kit installed (allowing fraction volumes up to 1,000 mL).

1001451 The CCC-1000 was operated in head-to-tail configuration and descending mode. The upper, stationary phase (methyl acetate) was pumped at a flow rate of 1.0 mL/min through the lower, stationary phase (0.1 M triethanolamine-pH 7.4) while rotation of the coils was held constant at 680 RPM. The sample was dissolved in 10.0 ml. of lower, stationary phase and injected directly into the system.

1001461 Preparation of tyro phase solvent system - The 0.1 M triethanolamine-pH
7.4 buffer was prepared by dissolving 13.25 mL of triethanolamine in 1.0 L. of deionized water. The pH was adjusted to 7.4 with dilute hydrochloric acid. The aqueous buffer was thoroughly mixed with methyl acetate by repeated mixing and settling using a large separatory funnel, and a small amount of lower phase added to the upper phase and vice versa to ensure the solutions were saturated.

1001471 Results - Figure 3 depicts a a representative chromatogram of a Meta-THc composition. The top panel identifies the chromatagraphic peaks comprising the Meta-THc components of the mixture whereas the subsequent panels describe the chromatagraphic profile of the isolation fractions comprising the peaks.

1001481 The percent homogeneity of each fraction, the amount isolated in each fraction and the percent recovery based upon the initial amount of material submitted to HSCCC purification are presented in Table 5 below.

(43) Table 5 Purity of fractions isolated by HSCCC
Purity of CCC fractions based on peak area HPLC, 254nm Vial 32 Vial 33 Vial 34 Vial 35 Vial 36 Vial 37 Vial 38 Vial 39 Vial 40 Vial 41 Vial 42 Vial 43 Vial 44 Vial 45 -- ----- -------- --------- --------- -------- --------- ---------TH1 79.5 82:8 77.5 57.1 _ 38.4 _11.9_ 0.9 _ 7H3 0.7 7.4 6.3 TH4 6.2 91.3 92.2 -------- ---- --------- --------- ----------=--------- --------- -------------------- --------- I --------- ---------TH5 3.9 28.5 52.5 84.3 97.6 98.9 99 99.1 92.4 =--------- ------ ---------- - ---------7H6 6.6 16.3 18.6 14.5 8.7 3.8 1.5 1.1 1 0.9 0.6 Example 3 Effects of Meta-THc on protein kinases 1001491 Methods - The dose responsiveness for kinase inhibition (reported as a percent of control) of a Meta-THc preparation and the individual components was tested at approximately 1, 5, 25, 50, and 100 ug/ml on 190 selected kinases as presented in Table I
below. The inhibitory effect of the present invention on human kinase activity was tested in the KinaseProfilerTM Assay (Upstate Cell Signaling Solutions, Upstate USA, Inc., Charlottesville, VA., USA). The assay protocols for specific kinases are summarized at http://www.upstate.com/img/pdf/kp protocols full.pdf (last visited on June 12, 2006).

1001501 Results - The inhibitory effects of Meta-THc on the kinases tested are shown in Tables 6 - 11 below.

Table 6 THI+2+4+5+7 Composite (Meta-TY[c) OG- OG- OG- OG- OG-3116 @ 3116 @ 3116 @ 3116 @ 3116 @
I lag/ml 5 g/ml 25 50 100 g/ml g/ml g/ml AbI (H3961!) (h) 91 88 73 55 50 Abl (M351T)(h) 100 87 62 50 38 Abi (Q252H) (h) 89 86 58 45 44 Abl(h) 98 85 65 41 49 Abl(m) 99 87 60 47 43 Abl(T3151)(h) 100 91 79 65 52 Abl(Y253F)(h) 93 90 75 54 51 (44) ACKI(h) 122 112 97 102 82 ALK(h) 76 38 17 16 26 ALK4(h) 96 95 85 68 48 Arg(h) 94 91 68 52 42 Arg(m) 100 99 94 73 50 ARKS(h) 100 97 82 64 75 Aurora-A(h) 92 79 40 41 27 Axl h) 97 99 83 77 60 Blk(m) 95 102 71 49 54 Bmx(h) 91 94 84 77 43 BrSKI(h) 95 90 71 47 51 BrSK2(h) 91 82 77 70 63 BTK(h) 99 97 64 44 28 CaMKI(h) 95 84 46 28 48 CaMKII(r) 97 106 89 69 63 CaMKII h) 94 99 85 52 34 CaMKIIy(h) 107 103 94 92 134 CaMKIIB(h) 103 97 84 83 84 CaMKIV(h) 107 108 95 75 58 CaMKIS(h) 91 93 92 75 80 CDK1/cyclinB(h) 99 101 91 71 58 CDK2/cyclinA(h) 105 106 92 83 63 CDK2/cyclinE(h) 99 103 75 60 42 CDK3/cyclinE(h) 108 100 96 79 45 CDK5/ 25(h) 102 89 84 77 72 CDKS/ 35(h) 95 84 82 67 68 CDK6/c clinD3(h) 109 109 99 22 87 CDKS/c clin T1(h) 96 98 78 67 64 CHK2(h) 86 95 92 95 86 CHK2(1157T)(h) 100 92 91 73 53 CHK2(R145W)(h) 100 96 93 89 69 CK1(y) 101 102 102 82 73 CK1 1(h) 93 89 82 50 47 CK1 2 h) 103 96 64 52 32 CKl 3(h) 96 92 53 29 27 CK16(h) 99 90 71 55 17 cKit(D816H)(h) 101 105 97 72 88 cKit(D816V)(h) 96 96 89 77 74 cKit(h) 84 86 64 71 76 cKit(V560G)(h) 97 104 87 82 78 cKit(V654A)(h 100 96 84 81 81 CLK2(h) 90 95 99 88 98 cSRC(h) 101 104 105 112 92 DAPK1(h) 69 39 26 19 22 DAPK2(h) 69 54 53 42 46 DCAMKL,2(h) 100 91 93 89 98 DRAKI (h) 96 103 89 70 78 EGFR(L858R)(h) 108 114 102 91 63 (45) EGFR L861Q)(h 93 94 81 71 66 EGFR(T790M)(h) 100 95 97 97 99 EGFR(T790M,1,858R)(h) 98 99 90 72 81 E hAl(h 105 100 102 84 80 EphA2(h) 105 105 99 93 66 E hA3(h 95 89 77 65 74 E hA8(h) 103 106 95 82 89 E hB l (h) 111 126 197 118 78 EphB3(h) 92 78 49 47 54 EphB4(h) 99 102 87 96 103 Fer(h) 74 85 88 94 94 Fes(h) 146 127 111 74 56 FGFR1(V561M)(h) 94 102 106 106 99 FGFR2(h) 91 87 79 53 66 FGFR2(N549H)(h) 98 102 101 88 82 FGFR3(h) 99 91 63 49 58 FGFR4(h) 93 70 40 37 41 F r(h) 99 93 92 94 97 Fltl(h) 96 97 94 88 85 Flt3(D835Y)(h) 96 104 101 95 92 Flt3(h) 108 103 91 79 59 Flt4(h) 103 112 90 69 52 Fms(h) 105 107 109 89 100 Fyn(h) 96 95 96 95 63 GRK7(h 100 104 104 92 104 GSK3u(h) 93 84 53 36 37 GSK3p(h) 95 86 39 24 39 Haspin(h) 100 93 96 63 48 Hck(h) 96 83 61 49 47 HIPK2(h) 104 107 107 101 103 IKKa(h) 106 121 112 110 100 IKK (h) 113 106 99 78 70 IR h) 81 88 53 59 59 IRAK1(h) 102 106 109 122 128 Itk(h) 99 102 96 101 86 JAK2(h) 98 105 98 94 85 JAK3(h) 91 77 73 64 47 JNK3(h) 98 98 90 78 78 Lck(h) 100 98 94 98 101 Lyn(h) 120 129 125 86 70 Lyn(m) 140 120 98 70 70 MAPKI(h), ERK1 82 80 61 53 52 MAPKAP-K2(h) 99 107 83 48 52 MAPKAP-K3(h) 94 73 96 93 86 MARKI(h 95 105 97 67 64 MELK(h) 102 99 96 92 95 Met(h) 109 119 88 52 68 MKK4(m) 96 115 88 87 101 (46) MKK7 (h 96 95 92 86 14 MLCK(h) 100 88 94 102 92 MRCKa(h) 97 100 100 91 90 MRCK (h) 102 106 102 100 75 MSK1(h) 99 102 78 51 46 MSK2(h) 99 84 63 33 31 MSSK1(h) 63 71 38 27 49 MST3(h) 117 117 71 25 28 MuSK(h) 105 106 96 92 94 NEK11(h) 93 92 90 65 43 NEK2(h) 98 103 113 115 82 NEK3(h) 99 98 94 105 84 NEK6(h) 95 99 90 72 32 NEK7(h) 98 99 89 86 67 NLK(h) 98 102 90 89 92 70S6K(h) 98 98 100 69 70 PAK2(h) 106 108 106 104 85 PAK3(h) 112 85 51 38 42 PAK4(h) 111 105 99 75 90 PAK5(h) 94 102 96 77 62 PAK6(h) 95 92 92 84 18 PAR-lBa(h) 99 111 101 81 89 PASK(h) 92 105 110 111 108 PDGFRa(D842V)(h) 100 103 104 97 101 PDGFRa(V561D)(h) 106 110 115 99 92 PDGFR (h 93 91 76 66 49 PDK1(h) 94 86 64 51 52 PhK 2(h) 112 92 95 49 41 P1 3-Kinase(h 94 95 89 54 49 PI3-Kinased(h) 95 84 33 15 35 PI3-Kinased(h) 100 91 31 5 -3 Pim-1(h) 108 103 92 65 45 Pim-2(h) 98 103 96 88 88 Pim-3(h) 104 99 96 102 108 PKA(h) 119 120 116 102 85 PKBu(h) 97 103 102 97 116 PKBR(h) 102 98 56 34 28 PKB (h) 97 100 97 84 90 PKCa(h) 97 101 91 81 75 PKC I(h 88 98 92 93 72 PKC II(h) 98 99 91 88 83 PKC (h) 100 102 89 86 70 PKC6(h) 86 104 83 75 99 PKCE(h) 98 98 92 87 97 PKCO(h) 95 100 116 92 100 PKG1a(h 98 97 100 93 71 P1k3(h) 91 94 86 79 83 PRAK(h) 68 36 17 12 18 (47) PrKX(h) 98 97 90 75 59 PTK5(h) 102 102 104 102 110 Ret (V804L)(h) 106 94 81 61 52 Ret(h) 111 99 98 84 81 Ret(V804M)(h) 103 98 90 90 84 ROCK-I(h) 107 96 89 74 83 Ron(h) 119 101 108 98 89 Rskl(h) 96 97 70 27 24 Rskl(r) 97 97 80 54 21 Rsk2(h) 97 95 51 34 27 Rsk3(h) 100 98 82 78 75 Rsk4(h) 94 81 46 28 20 SAPK2b(h) 108 103 103 102 116 SAPK3(h 98 105 104 113 113 SAPK4(h) 101 105 110 111 108 SGK(h) 97 101 100 81 60 SGK2(h) 92 107 88 73 62 SIK(h) 97 97 78 60 41 Src(1-530)(h) 105 101 101 90 37 SRPK1(h) 90 83 19 43 33 SRPK2(h) 105 101 88 98 85 S k(h) 120 127 87 54 39 TBK1(h) 98 99 94 100 69 Tie2(h) 99 91 73 53 62 Tie2(R849W)(h) 88 42 40 51 55 Tie2(Y897S)(h) 75 44 34 24 26 TLK2(h 94 98 91 85 107 TrkA h) 103 98 42 8 23 TrkB(h) 107 137 135 111 55 TSSK1(h) 96 97 92 87 78 TSSK2(h) 100 99 92 91 85 Txk(h) 99 105 114 122 112 ULK2(h 105 116 92 44 81 WNK3(h) 98 104 108 110 103 Yes(h 96 88 84 87 102 ZAP-70(h) 105 103 99 96 101 ZIPK(h) 103 91 79 65 78 Table 7 OG- OG- OG- OG- OG-3306 @ 3306 @ 3306 @ 3306 @ 3306 @
I g/ml 5 g/ml 25 50 100 g/ml tag/m1 [ig/m1 Abl (H396P) (h) 100 90 89 79 47 (48) Abl (M351T)(h 96 95 89 79 45 Abl (Q252H) (h) 101 93 82 72 36 Abl(h) 96 88 78 60 35 Abl(m) 48 99 77 65 50 Abl(T3151)(h) 99 95 93 89 65 Abl(Y253F)(h) 101 102 94 81 47 ACK1(h) 112 101 106 100 92 ALK(h) 78 49 29 20 18 ALK4(h) 110 91 102 93 65 Arg(h) 77 88 88 64 45 Arg(m) 106 105 108 107 52 ARK5(h) 110 105 97 88 74 Aurora-A(h) 110 102 85 52 48 Axl(h) 107 108 103 91 68 Blk(m) 121 103 100 81 60 Bmx(h) 93 93 92 83 49 BrSK1(h) 100 95 96 79 53 BrSK2(h) 97 92 93 78 61 BTK(h) 99 99 79 68 34 CaMKI(h) 90 94 74 47 37 CaMKII(r) 113 110 114 104 73 CaMKII h) 107 105 100 83 55 CaMKII (h) 103 109 101 109 106 CaMKIIS(h) 106 96 90 98 86 CaMKIV(h) 104 113 114 102 49 CaMK18(h 93 90 96 91 80 CDKI/c clinB(h) 103 102 99 94 74 CDK2/c clinA(h) 114 112 108 97 83 CDK2/c clinE(h) 93 103 91 78 52 CDK3/cyclinE(h) 112 116 103 112 59 CDK5/p25(h) 105 95 98 95 69 CDK5/ 35(h) 105 110 97 91 68 CDK6/c clinD3(h) 115 110 99 106 96 CDK9/c clip T1(h) 95 97 97 86 70 CHK2(h) 105 111 106 27 87 CHK2(1157T)(h) 103 104 93 96 64 CHK2(R145W)(h) 97 94 93 96 64 CK1(y) 113 117 108 111 83 CKl 1(h 100 101 97 83 38 CK1 2(h 99 96 91 69 35 CK1 3(h 106 101 95 63 43 CK16(h) 121 102 95 85 35 cKit(D816H)(h) 124 109 113 115 95 cKit(D816V)(h) 113 108 101 86 56 cKit(h) 105 110 79 97 89 cKit V560C)(h) 115 109 107 104 91 cKit(V654A)(h) 108 110 103 103 85 CLK2(h) 108 104 104 98 93 (49) cSRC(h) 103 98 97 97 83 DAPK1(h) 76 49 32 27 22 DAPK2(h) 66 61 51 53 36 DCAMKL2(h) 101 100 95 96 76 DRAK1(h) 104 103 99 90 79 EGFR(L858R)(h) 114 107 107 97 67 EGFR(L861Q)(h) 113 109 104 95 62 EGFR(T790M)(h) 107 N04 103 104 101 EGFR(T790M,1,858R)(h) 109 1 102 95 81 EphAl(h) 107 110 119 87 EphA2(h) 90 107 83 73 EphA3(h) 105 104 96 85 73 E hA8(h) 113 99 109 104 98 EphBl(h) 109 116 128 172 120 E hB3(h) 111 71 58 51 58 EphB4(h) 102 98 95 103 108 Fer(h) 104 102 91 66 61 Fes(h) 137 132 121 117 43 FGFR1(V561M)(h) 94 96 97 94 97 FGFR2(h) 109 100 75 63 66 FGFR2(N549H)(h) 109 106 105 107 97 FGFR3(h) 89 95 73 63 46 FGFR4(h) 98 96 60 35 25 Fgr(h) 108 106 102 92 81 Fitl (h 105 104 102 103 92 Flt3(D835Y)(h) 104 101 95 94 91 Flt3(h) 108 106 103 100 61 Flt4(h) 109 104 100 85 75 Fms(h) 111 114 121 122 96 Fyn(h) 111 111 107 104 67 GRK7(h) 98 100 95 97 103 GSK3a(h) 110 90 67 47 22 GSK3 (h) 102 96 66 45 36 Has in(h) 89 84 89 96 63 Hck h) 109 99 85 70 50 HIPK2(h) 108 105 112 106 88 IKKa(h) 101 113 110 121 105 IKK (h) 97 97 103 101 71 IR(h) 100 99 95 85 81 IRAK1(h) 109 111 112 112 112 Itk(h 76 107 105 101 104 JAK2(h) 105 112 106 105 96 JAK3(h) 100 96 88 84 65 JNK3(h) 105 105 105 93 82 Lck(h) 104 102 105 101 91 Lyn(h) 153 145 151 119 49 L n(m) 91 88 108 118 113 MAPK1(h), ERKI 89 90 76 55 63 (50) MAPKAP-K2(h) 107 112 112 92 64 MAPKAP-K3(h 100 98 103 105 98 MARK1(h) 99 90 16 96 61 MELK(h) 105 99 97 97 86 Met(h) 109 118 146 91 68 MKK4(m) 112 118 109 107 107 MKK7 (h) 12 19 40 94 81 MLCK(h) 93 98 101 94 96 MRCKa(h) 113 103 102 107 95 MRCK (h) 103 106 112 110 86 MSKI(h) 104 101 100 83 43 MSK2(h) 101 92 86 70 31 MSSK1(h) 115 105 51 31 41 MST3(h) 98 107 119 108 58 MuSK(h) 98 99 102 103 99 NEK11(h) 99 83 60 40 36 NEK2(h) 97 97 104 115 99 NEK3(h) 99 100 99 97 97 NEK6(h) 90 92 84 80 46 NEK7(h) 113 103 98 108 81 NLK(h) 108 103 99 96 98 70S6K(h) 111 104 116 103 95 PAK2(h) 121 115 116 111 102 PAK3(h) 121 107 59 51 37 PAK4(h) 106 96 107 113 109 PAK5(h) 101 99 103 97 70 PAK6(h) 93 80 92 88 32 PAR-IBa(h) 110 106 110 115 103 PASK(h) 109 105 122 117 102 PDGFRa(D842V)(h) 129 122 131 123 101 PDGFRa(V561D) h) 113 114 121 117 103 PDGFR (h) 54 95 80 100 110 PDK1(h) 98 87 84 67 69 PhK 2(h) 117 119 111 93 50 PI3-Kinase (h) 97 98 81 60 34 PI3-Kinase6(h) 98 96 77 64 26 PI3-Kinase6(h) 89 88 70 47 58 Pim-1(h) 108 111 107 110 54 Pim-2(h) 100 97 100 92 81 Pim-3(h) 103 97 98 102 99 PKA(h) 95 102 110 112 117 PKBa(h) 125 130 119 125 103 PKBR(h) 97 99 85 67 36 PKBy(h) 109 103 97 101 86 PKCa(h) 102 104 96 93 72 PKC I(h) 46 42 55 97 81 PKC II(h) 114 116 108 103 82 PKC7(h) 112 110 106 98 71 (51) PKC6(h 118 118 107 99 97 PKCO(h) 111 103 97 96 94 PKCO(h) 99 92 104 102 98 PKG1a(h) 107 103 106 103 83 P1k3(h) 113 110 110 101 99 PRAK(h) 80 50 26 23 20 PrKX(h) 102 101 92 91 61 PTK5(h) 107 111 106 115 105 Ret (V804L)(h) 107 97 102 87 72 Ret(h) 117 107 108 114 83 Ret(V804M)(h) 106 100 107 117 92 ROCK-I(h) 110 110 98 106 80 Ron(h) 112 111 127 126 85 Rskl(h) 100 97 102 68 44 Rskl(r) 105 96 99 91 43 Rsk2(h) 105 100 92 69 40 Rsk3(h) 111 102 105 98 95 Rsk4(h) 88 78 68 51 24 SAPK2b(h) 103 112 92 116 116 SAPK3(h) 113 108 109 118 109 SAPK4(h) 117 115 109 114 114 SGK(h) 96 97 102 91 87 SGK2(h) 114 121 123 106 78 SIK(h) 105 99 97 91 46 Src(1-530)(h) 101 105 103 98 57 SRPK1(h) 95 46 51 55 38 SRPK2(h) 107 112 100 93 85 Syk(h) 92 107 96 69 77 TBK1 h) 94 95 92 90 77 Tie2(h) 111 103 73 59 45 Tie2(R849W)(h) 97 56 40 55 58 Tie2(Y897S)(h) 84 53 41 34 26 TLK2(h) 101 105 101 98 97 TrkA(h) 106 107 100 55 10 TrkB(h) 120 111 117 112 85 TSSK1(h) 106 103 93 92 81 TSSK2(h) 109 103 97 103 84 Txk(h 114 101 102 104 113 ULK2(h) 113 109 108 106 109 WNK3(h) 104 105 109 113 115 Yes(h) 1 1 0 i l l 109 110 91 ZAP-70(h) 124 119 119 123 116 ZIPK(h) 108 102 98 96 77 Table 8 (52) oc- oG- 0G- 0G- OG-3307 @ 3307 a 3307 @ 3307 @ 3307 @
1 g/ml 5 g/m1 25 50 100 g/ml g/ml g/ml Abl (H396P) (h) 96 103 83 65 54 Abl M351T)(h 92 95 89 75 56 Abl (Q252H) (h) 96 96 66 68 47 Abl(h) 92 87 70 64 40 Abl(m) 98 91 69 32 48 Abl T3151)(h) 102 98 79 68 58 Abl(Y2531 (h 117 100 83 65 58 ACK1(h 117 124 97 86 81 ALK(h) 80 59 21 21 23 ALK4(h) 109 104 97 83 63 Ar (h 92 92 69 53 43 Arg(m) 100 101 103 88 62 ARKS(h) 103 104 99 77 74 Aurora-A(h) 65 24 71 57 54 Axl(h) 106 110 100 86 65 Blk(m) 108 115 96 72 53 Bmx(h) 88 90 89 79 61 BrSK1 h) 104 101 82 66 50 BrSK2(h) 99 90 84 83 72 BTK(h) 98 96 67 59 47 CaMKI(h) 96 93 73 48 48 CaMKII(r) 105 106 105 91 63 CaMKI! (h) 103 106 95 83 66 CaMKII h) 109 109 131 108 101 CaMKIIB h 99 99 100 91 87 CaMKIV(h) 117 126 86 69 52 CaMKI$(h) 95 88 101 105 98 CDK1/cyclinB(h) 111 111 90 86 74 CDK2/c clinA(h) 114 124 95 98 87 CDK2/cyclinE(h) 95 101 93 71 54 CDK3/c clinE(h) 102 104 120 103 84 CDK5/ 25(h 93 96 103 88 77 CDK5/ 35(h 105 98 106 80 90 CDK6/c clinD3(h 120 109 117 105 92 CDK9/cyclin TI(h) 99 102 78 63 49 CHK2 h) 107 107 105 108 97 CHK2 1157T (h) 108 104 94 83 74 CHK2 R145W)(h) 110 112 99 86 80 CK1( 114 113 110 110 100 CK1 1(h) 100 101 88 73 48 CKly2(h) 103 96 79 54 49 CKly3(h) 96 91 83 43 34 CK16(h) 105 112 108 80 53 cKit(D816H)(h) 123 116 104 114 108 (53) cKit(D816V)(h) 109 105 98 82 87 cKit(h 110 87 86 96 95 cKit(V560G)(h) 112 114 105 90 78 cKit(V654A)(h) 100 101 112 88 75 CLK2(h) 103 100 110 101 96 cSRC(h) 114 114 108 101 87 DAPKI(h 63 40 32 25 19 DAPK2(h) 61 56 55 52 49 DCAMKL2(h) 96 100 110 96 86 DRAK1(h) 103 106 107 93 79 EGFR(L858R)(h) 109 117 104 90 70 EGFR(L861Q)(h) 98 91 94 99 93 EGFR(T790M)(h) 106 104 104 100 102 EGFR(T790M,L858R)(h) 104 109 95 94 82 EphAl(h) 117 116 108 99 85 E hA2(h 102 104 105 99 92 EphA3(h) 93 91 98 87 84 EphA8(h) 118 99 112 101 100 EphBl(h) 127 82 144 195 105 E hB3(h) 80 71 69 62 57 EphB4(h) 106 112 116 109 98 Fer(h) 110 102 104 91 88 Fes(h) 140 120 105 99 86 FGFR1(V561M)(h) 105 107 95 79 75 FGFR2(h) 111 98 102 96 78 FGFR2(N549H)(h) 110 102 103 103 82 FGFR3(h) 94 92 67 64 51 FGFR4(h) 89 81 55 64 55 F r(h) 95 96 112 106 86 Fltl(h) 102 97 103 102 98 F1t3(D835Y)(h) 108 116 102 105 98 Fltl(h) 107 99 109 95 84 Flt4 h 117 113 88 80 55 Fms(h) 116 103 121 117 98 Fyn(h) 103 105 103 105 89 GRK7(h) 110 95 102 91 99 GSK3a(h) 94 92 61 51 43 GSK3 (h) 98 86 55 44 40 Has in(h) 105 95 90 76 49 Hck(h) 103 88 76 62 42 HIPK2(h) 120 111 115 110 97 IKKa(h) 99 108 114 114 120 IKKj3(h) 111 107 94 77 76 IR(h) 96 100 80 75 79 IRAK1(h) 99 112 37 39 39 Itk(h) 101 103 87 82 87 JAK2(h) 108 119 101 95 89 JAK3(h) 74 67 62 53 35 (54) JNK3(h) 110 108 80 92 88 Lck(h) 106 111 86 83 78 L n(h) 145 146 139 91 68 Lyn(m) 116 110 76 58 68 MAPK1(h), ERKI 93 83 72 75 67 MAPKAP-K2(h) 116 104 104 74 73 MAPKAP-K3(h) 101 100 109 104 101 MARKI(h) 109 110 97 90 63 MELK(h) 116 104 102 98 83 Met(h) 114 113 97 83 61 MKK4(m) 120 127 91 95 85 MKK7 (h) 100 110 111 82 72 MLCK(h) 98 96 105 93 86 MRCKa(h) 100 94 112 102 97 MRCK (h) 110 114 109 104 99 MSK1(h) 98 103 92 64 52 MSK2(h) 99 94 70 51 37 MSSKI(h) 105 84 43 50 39 MST3(h) 107 89 87 46 45 MuSK(h) 104 101 99 98 97 NEK11(h) 97 106 96 75 51 NEK2(h) 106 109 105 102 72 NEK3(h) 99 102 97 94 92 NEK6(h) 103 100 79 67 53 NEK7(h) 103 107 98 95 84 NLK(h) 105 104 98 96 85 70S6K(h) 108 108 108 92 69 PAK2(h) 116 110 107 101 96 PAK3(h) 103 102 49 47 40 PAK4(h) 105 84 98 110 99 PAKK(h 106 105 91 93 61 PAK6(h) 85 113 90 89 42 PAR-lBa(h) 109 113 114 116 88 PASK(h) 71 76 78 80 71 PDGFRa(D842V)(h) 113 124 128 129 127 PDGFRa(V561D)(h) 115 126 116 111 103 PDGFR(3(h) 111 110 53 50 44 PDKI h 122 123 102 87 69 PhKy2(h) 112 116 114 88 63 PI3-Kinase (h) 99 95 75 47 28 PI3-KinaseS(h) 95 100 72 42 19 PI3-Kinase6(h) 97 89 62 18 52 Pim-1(h) 86 100 87 84 55 Pim-2(h) 103 111 77 73 67 Pim-3(h) 104 104 72 70 64 PKA(h) 131 124 93 94 86 PKBa(h 123 130 126 118 79 PKBD(h) 104 97 68 43 31 (55) PKB (h) 112 110 107 97 83 PKCa(h) 103 99 98 98 71 PKC I h) , 105 110 93 95 92 PKC II(h) 107 105 99 103 98 PKC7(h) 102 107 101 91 99 PKC6(h) 111 110 97 92 80 PKCE(h) 105 102 98 102 90 PKCO(h 101 84 116 96 83 PKGla(h) 103 112 97 92 73 Plk3(h) 120 105 104 99 86 PRAK(h) 66 45 19 24 19 PrKX h) 101 103 98 88 66 PTK5(h) 116 105 113 112 116 Ret (V804L)(h) 110 103 91 81 60 Ret(h) 112 115 101 100 68 Ret(V804M)(h) 107 104 110 94 88 ROCK-I(h) 110 111 110 100 88 Ron(h) 123 124 123 116 94 Rskl(h) 97 95 65 53 32 Rskl(r) 101 102 93 63 36 Rsk2(h) 102 100 81 43 32 Rsk3(h) 112 106 97 88 85 Rsk4(h) 79 71 47 31 17 SAPK2b(h) 117 110 108 108 111 SAPK3(h) 109 99 114 122 106 SAPK4(h) 114 118 116 121 109 SGK(h) 106 96 97 92 76 SGK2(h) 133 116 112 121 69 SIK(h) 102 99 104 89 62 Src(1-530)(h) 103 105 105 102 75 SRPK1(h) 47 89 61 53 45 SRPK2(h) 105 104 99 91 88 Syk(h) 135 120 63 37 47 TBK1(h) 108 107 97 86 70 Tie2(h) 110 96 74 80 78 T1e2(R849)y)(h) 91 53 48 43 46 Tie2(Y897S)(h) 82 46 27 35 32 TLK2(h 98 89 106 94 98 TrkA(h) 110 ill 99 31 25 TrkB(h) 136 132 144 118 78 TSSKI(h) 105 97 96 91 86 TSSK2(h) 106 99 100 97 87 Txk(h) 114 121 121 110 107 ULK2(h) 102 52 77 106 105 WNK3(h) 111 113 109 113 111 Yes(h) 92 81 116 111 104 ZAP-70(h) 125 110 124 124 107 ZIPK(h) 106 96 91 81 76 (56) Table 9 OG- OG- OG- OG- OG-3308 @ 3308 @ 3308 @ 3308 @ 3308 @
I g/ml 5 g/ml 25 50 100 g/ml pg/ml gg/ml Abl (H396P) (h) 106 102 73 35 11 Abl (M351T)(h) 96 98 68 40 11 Abi (Q252H) (h) 96 97 62 39 10 Abl(h) 87 84 52 33 0 Abl(m) 95 87 60 39 11 Abl T315I)(h) 100 93 75 60 17 Abl(Y253F)(h) 105 96 69 49 16 ACK1(h) 100 103 95 96 58 ALK(h 62 27 15 28 17 ALK4(h) 109 102 100 85 49 Arg(h) 85 79 61 26 10 Ar (m) 103 109 79 50 6 ARKS(h) 103 102 85 74 63 Aurora-A(h 84 72 48 15 5 Axl(h 118 106 94 75 56 Blk(m) 109 112 70 53 12 Bmx(h) 83 99 88 40 2 BrSK1(h) 107 80 71 38 15 BrSK2(h) 88 77 65 45 14 BTK(h) 99 98 64 14 4 CaMKI(h 97 81 48 31 16 CaMKII(r) 103 104 101 82 38 CaMKII(3(h) 100 98 81 35 9 CaMKII h) 100 103 107 92 80 CaMKIIB(h) 97 100 83 66 51 CaMKIV(h) 130 125 103 86 44 CaMK16(h) 85 91 89 63 19 C1)K1/c clinB(h) 109 110 100 71 23 CDK2/cyclinA(h) 118 111 104 82 32 CDK2/c clinE(h) 96 98 73 44 4 CDK3/cyclinE(h) 101 107 43 23 3 CDK5/ 2S(h) 86 88 76 46 2 CDK5/p35(h) 106 104 81 68 18 CDK6/c clinD3 h) 104 103 105 99 4 CDK9/cyclin T1(h) 86 87 74 64 28 CHK2(h) 107 89 104 72 28 CHK2(1157T)(h) 101 97 75 53 20 CHK2(R145W (h) 94 99 93 63 26 CK1(y) 111 106 104 91 21 (57) CKl 1(h) 88 91 58 25 12 CK1 2(h) 92 90 55 20 9 CK1 3(h 89 87 51 39 8 CK16(h 100 102 75 12 3 cKit(D816H)(h) 118 123 111 92 83 cKit(D816V)(h) 104 104 88 74 68 cKit(h) 97 94 94 89 90 cKit(V560G (h) 120 111 99 52 34 cKit(V654A)(h) 96 98 89 74 53 CLK2(h) 101 101 99 93 23 cSRC(h) 101 87 101 88 35 DAPKI(h) 73 54 33 29 19 DAPK2(h) 69 67 57 39 44 DCAMKL2(h) 70 78 75 50 12 DRAK1(h) 101 102 90 77 52 EGFR(L858R)(h) 105 105 92 56 5 EGFR(L861Q)(h) 105 107 93 73 13 EGFR(T790M) h) 105 112 106 104 15 EGFR(T790M,L858R)(h) 105 98 93 84 52 EphAl(h) 105 121 106 92 74 EphA2(h) 118 115 93 88 23 EphA3(h) 103 100 95 83 89 E hA8(h) 104 118 108 94 64 EphBl(h) 104 123 161 106 45 EphB3(h) 77 79 62 70 77 E hB4(h 94 99 98 90 105 Fer(h) 89 87 83 75 35 Fes(h) 150 166 134 68 13 FGFR1(V561M) h 74 74 80 82 61 FGFR2(h) 86 84 61 53 35 FGFR2(N549H)(h) 107 104 106 95 25 FGFR3(h) 99 96 57 45 54 FGFR4(h) 111 85 41 24 25 F r(h) 103 104 105 69 2 Fltl(h) 97 105 100 94 87 Flt3(D835Y)(h) 99 101 102 85 13 Flt3(h) 103 107 95 62 59 Flt4(h) 104 91 95 67 29 Fms(h) 114 119 104 93 63 Fyn(h) 86 86 72 31 14 GRK7(h) 96 94 98 101 85 GSK3a(h) 85 80 40 12 2 GSK3 (h) 92 71 42 30 -8 Haspin(h) 85 95 80 53 11 Hck(h) 99 93 63 38 6 HIPK2(h) 117 113 116 118 68 IKKa(h) 107 126 127 101 33 1KK(3(h) 111 117 104 72 23 (58) IR h) 95 104 87 97 93 IRAK1(h) 36 39 41 46 39 Itk(h 81 86 82 91 65 JAK2(h) 104 97 98 87 76 JAK3(h) 77 69 58 28 4 JNK3(h) 111 101 98 78 53 Lck(h) 88 84 79 84 78 Lyn(h) 151 144 120 95 49 Lyn(m) 124 118 108 92 76 MAPK1(h), ERK1 109 85 72 64 42 MAPKAP-K2(h) 111 108 88 59 28 MAPKAP-K3(h) 106 107 103 91 15 MARK1(h) 112 95 84 65 31 MELK(h) 101 97 90 88 49 Met(h) 120 121 89 62 18 MKK4(m) 104 112 99 107 76 MKK70(h) 92 89 82 85 50 MLCK(h) 90 94 95 89 78 MRCKa(h) 97 96 99 81 49 MRCK (h 111 113 109 85 13 MSKI(h 106 105 72 51 8 MSK2(h) 87 92 51 37 11 MSS)__ 103 63 49 50 45 MST3(h) 110 119 74 51 15 MuSK(h) 110 87 82 82 81 NEK11(h) 97 80 42 33 33 NEK2(h) 94 45 50 45 17 NEK3(h) 94 90 86 68 38 NEK6(h 64 60 48 21 7 NEK7(h) 103 108 101 75 31 NLK(h) 100 106 95 88 70 70S6K(h) 100 96 90 70 67 PAK2(h 108 101 109 94 34 PAK3(h) 110 81 41 32 11 PAK4(h) 107 119 99 93 70 PAKS(h 98 104 109 70 12 PAK6(h) 92 97 64 19 -3 PAR-1Ba(h) 108 104 98 78 54 PASK(h) 73 75 77 60 8 PDGFRa(D842V)(h) 135 117 110 93 56 PDGFRa(V561D)(h) 124 116 105 86 55 PDGFR (h) 59 55 71 69 91 PDK1(h) 123 114 94 87 60 PhKy2(h) 84 84 57 25 6 PI3-Kinase (h) 51 100 37 27 11 PI3-Kinase6(h) 98 97 49 33 20 PI 3-Kinase8(h) 34 92 40 50 35 Pim-1(h) 86 92 82 52 15 (59) Pim-2(h) 80 76 71 64 40 Pim-3(h) 71 73 72 69 51 PKA(h) 106 115 123 107 29 PKBa(h) 84 97 86 67 52 PKB (h) 87 93 66 39 6 PKB h) 116 114 115 104 80 PKCa(h) 99 95 91 84 66 PKC I(h) 104 105 92 94 104 PKC II(h 109 108 98 105 99 PKCy(h) 100 103 93 97 80 PKCy(h) 102 105 97 95 94 PKCy(h) 103 104 96 98 98 PKCO(h) 89 92 101 90 51 PKGla(h) 97 94 94 64 31 Plk3(h) 110 111 110 100 92 PRAK(h) 61 35 20 33 24 PrKX(h) 96 93 81 49 2 PTK5(h) 110 108 106 106 31 Ret (V804L)(h) 110 95 78 57 37 Ret(h) 111 115 98 70 23 Ret(V804M)(h) 111 128 118 90 46 ROCK-I(h 107 109 102 90 46 Ron(h) 115 120 120 93 31 Rskl(h) 89 101 62 18 4 Rskl r) 95 97 59 25 2 Rsk2(h) 102 101 46 21 7 Rsk3(h) 111 113 100 85 65 Rsk4(h) 88 80 34 18 10 SAPK2b(h) 102 99 103 112 63 SAPK3 h) 94 93 96 91 55 SAPK4(h) 105 106 113 109 65 SGK(h) 91 90 93 61 12 SGK2(h) 114 115 97 61 15 SIK(h) 98 94 86 34 10 Src 1-530 (h 101 100 88 38 5 SRPK1(h) 100 91 59 27 29 SRPK2(h) 103 110 88 87 61 S k(h 119 127 83 61 54 TBKI(h) 86 90 90 85 83 Tie2(h) 111 89 63 46 25 Tie2(R849W)(h) 77 43 67 49 46 Tie2(Y897S)(h) 71 44 25 16 9 TLK2(h) 98 97 96 91 78 TrkB(h) 93 103 38 12 7 TrkB(h) 114 130 129 53 18 TSSKI(h) 100 99 97 91 14 TSSK2(h) 104 101 105 84 17 (60) Txk(h) 99 102 111 106 37 ULK2(h) 113 112 113 97 36 WNK3(h) 109 107 115 106 87 Yes(h) 113 113 112 94 8 ZAP-70(h 71 67 61 56 33 ZIPK(h) 105 109 93 75 50 Table 10 TH-S
OG- OG- OG- OG- OG-@ 1 a 5 @ 25 @ 50 @ 100 g/ml g/ml g/ml g/ml g/inl Abl (1396P) (h) 112 103 79 45 10 Abi (M351T)(1i104 105 72 38 8 AbI (Q252LI (h) 103 93 72 48 16 Abl(h 97 80 58 25 2 Abl(m) 102 61 54 40 11 Abl(T3151)(h) 103 96 76 57 16 Abl(Y253F)(h) 100 99 70 51 14 ACK1(h 116 115 97 87 46 ALK(h) 83 39 15 24 14 ALK4(h) 112 103 91 84 43 Arg(h) 100 95 73 27 11 Arg(m) 118 105 96 60 6 ARKS(h) 108 103 78 68 61 Aurora-A(h) 105 92 57 15 10 Axl h) 113 114 94 81 53 Blk(m 144 124 62 47 14 Bmx(h) 95 89 86 46 1 BrSK1(h) 102 95 75 43 12 BrSK2(h) 90 76 68 44 15 BTK(h) 108 100 62 15 5 CaMKI(h) 93 71 30 16 18 CaMKII(r) 109 113 98 70 43 CaMKII (h) 107 104 72 24 9 CaMKII (h) 126 111 100 86 68 CaMKI16(h) 103 102 82 63 58 CaMKIV(h) 120 123 96 93 42 CaMKIV(h) 98 89 71 47 14 CDKI/c clinB(h) 100 107 91 71 32 CDK2/c clinA(h) 116 110 101 75 21 CDK2/c clinE(h) 101 96 78 52 4 CDK3/c clinE(h) 57 59 50 27 10 CDK5/p25(h) 101 84 85 57 5 CDK5/p35(h) 164 131 121 101 31 (61) CDK6/c clinD3(h) 121 107 92 82 13 CDK9/cyclin T1(h) 102 93 75 71 40 CHK2(h) 116 104 106 63 26 CHK2(1157T)(h) 108 98 88 51 18 CHK2(R145W)(h) 109 101 98 62 23 CKI 1(h) 97 91 70 34 20 CK1 2(h) 103 98 65 23 17 CK1 3(h) 103 96 49 33 11 CK16(h 115 103 78 30 3 cKit(D81611)(h) 111 108 102 86 72 cKit(D816V)(h) 108 107 87 52 51 cKit(h 117 99 92 94 89 cKit(V560G)(h) 111 106 96 69 28 cKit(V654A)(h) 101 97 87 70 56 CLK2(h) 111 108 105 87 18 cSRC(h) 109 99 90 79 38 DAPK1(h) 65 35 22 18 12 DAPK2(h) 71 61 54 41 37 DCAMKL2(h) 101 82 81 57 21 DRAK1(h) 111 107 93 77 59 EGFR(L858R)(h) 120 116 101 71 5 EGFR(1,861Q (h) 110 106 104 75 17 EGFR(T790M)(h) 105 109 99 91 15 EGFR(T790M,L858R)(h) 110 107 94 85 42 E hA1 h) 115 112 110 82 69 EphA2(h) 125 128 106 98 14 EphA3(h) 113 100 96 92 92 E hA8(h) 115 116 106 94 76 E hEl(h) 106 120 159 102 45 E hB3 h) 80 69 56 51 50 EphB4(h) 103 104 93 84 97 Fer(h) 117 105 84 78 71 Fes(h) 171 150 108 56 15 FGFR1(V561M)(h) 84 79 75 73 53 FGFR2(h) 109 99 54 55 68 FGFR2(N549H)(h) 107 108 102 81 23 FGFR3(h) 94 90 50 65 65 FGFR4(h) 112 100 46 60 55 Fgr(h) 116 107 97 87 10 Fltl(h) 107 101 93 89 80 F1t3(D835Y)(h) 105 108 92 74 22 Flt3(h) 112 86 102 85 11 F1t4(h) 108 98 77 57 29 Fms(h) 114 118 112 99 69 Fyn(h) 89 80 76 45 12 GRK7(h) 104 92 87 88 86 GSK3a(h) 98 84 43 21 8 (62) GSK3 (h) 91 68 43 34 15 Has in h) 79 73 67 39 17 Hck(h) 92 84 56 35 12 HIPK2(h 120 117 107 104 65 IKKa(h) 124 131 125 108 50 IKK h 120 118 100 70 31 IR(h) 91 99 90 85 77 IRAK1(h 43 39 41 43 39 Itk(h) 91 90 85 90 77 JAK2(h) 112 111 95 89 62 JAK3(h) 80 72 58 20 5 JNK3(h) 87 96 95 83 65 Lck(h) 86 91 85 75 63 Lyn(h) 154 149 126 95 49 Lyn(m) 92 98 77 100 65 MAPK1(h), ERK1 108 93 75 62 44 MAPKAP-K2(h) 122 110 91 61 41 MAPKAP-K3(h) 113 110 106 100 25 MARK1(h) 109 97 83 60 29 MELK(h) 108 103 92 77 46 Met(h) 121 126 80 57 17 MKK4(m) 89 91 95 82 60 MKK7 (h) 109 90 71 62 37 MELK(h) 101 104 91 84 70 MRCKa(h) 105 102 103 90 32 MRCK h 111 110 108 90 16 MSKI(h) 117 106 75 49 8 MSK2(h) 106 89 39 25 11 MSSKI(h) 114 75 45 53 16 MST3(h) 98 95 81 39 16 MuSK(h) 78 80 81 86 84 NEK11(h) 110 102 79 48 36 NEK2(h) 56 56 62 67 23 NEK3(h) 90 92 76 71 37 NEK6(h) 77 77 65 30 6 NEK7(h) 106 105 96 74 10 NLK(h) 112 108 91 84 75 70S6K(h) 108 104 93 70 37 PAK2(h) 119 125 116 99 39 PAK3(h) 107 78 50 36 13 PAK4(h) 112 114 90 102 95 PAK5(h) 111 109 105 77 15 PAK6(h) 98 111 91 29 14 PAR-1Ba(h) 114 113 103 90 48 PASK(h) 68 70 73 71 15 PDGFRa(D842V)(h) 141 138 143 122 55 PDGFRa(V561D (h) 109 119 116 90 43 PDGFR(3(h) 59 53 54 64 78 (63) PDK1(h) 127 117 93 95 67 PhK72(h) 96 89 52 30 13 PI3-Kinase (h 96 88 49 38 15 PI3-KinaseS(h 102 99 56 25 31 PI3-Kinase6(h) 96 86 38 8 4 Pim-1(h 95 92 75 44 21 Pim-2(h) 84 80 72 69 17 Pim-3(h) 73 67 65 65 71 PKA(h) 98 96 91 89 23 PKBa(h) 102 91 83 75 58 PKB (h) 112 108 63 37 6 PKB (h) 119 113 103 104 46 PKCu(h) 105 103 100 83 72 PKC I(h) 102 102 95 84 72 PKC II(h) 108 106 100 81 79 PKCO(h) 98 96 99 68 71 PKCO(h) 105 106 90 94 84 PKCO(h) 112 107 85 87 91 PKCO(h) 100 92 89 89 71 PKG l a(h) 101 94 92 65 24 Plk3(h) 120 118 106 99 98 PRAK(h 86 47 23 21 24 PrKX(h) 106 95 83 54 2 PTK5(h) 111 110 98 103 48 Ret (V804L)(h) 120 116 87 64 39 Ret(h) 117 105 98 74 28 Ret(V804M)(h) 133 129 119 97 46 ROCK-I(h) 123 119 100 91 50 Ron(h) 130 120 110 89 32 Rsk1(h 109 101 71 36 5 Rskl(r) 110 101 74 37 4 Rsk2(h) 113 103 44 36 12 Rsk3(h) 122 104 85 83 72 Rsk4(h) 96 82 37 20 7 SAPK2b(h 105 117 104 101 70 SAPK3(h) 110 109 107 96 63 SAPK4(h) 110 116 108 104 74 SGK(h) 102 97 90 69 15 SGK2(h) 116 103 98 65 37 SIK h) 106 97 82 38 8 Src(1-530)(h) 113 108 100 63 6 SRPK1(h) 101 92 51 42 19 SRPK2(h) 96 91 89 75 58 Syk(h) 104 78 43 61 64 TBK1(h) 104 93 80 67 51 Tie2(h 89 90 77 72 71 Tie2(R849W)(h) 90 44 56 53 57 (64) Tie2(Y897S)(h) 57 38 17 22 27 TLK2(h) 103 98 96 92 81 TrkA(h) 97 92 38 10 7 TrkB(h) 120 116 131 75 1 TSSK1(h) 105 103 94 84 20 TSSK2(h) 106 106 95 81 14 Txk(h) 111 109 102 99 66 ULK2(h) 73 111 105 103 93 WNK3(h) 108 112 114 113 80 Yes(h) 116 117 115 105 20 ZAP-70(h) 75 77 66 61 41 ZIPK(h) 110 93 87 80 34 (65) Table 11 OG- OG- OG- OG- OG-@ 1 @ 5 @ 25 @ 50 @ 100 g/m1 g/ml g/ml g/ml g/ml Abl(H396P (h) 105 103 89 68 18 Abi (M351T)(h) 93 92 67 59 19 Abl (Q252H) (h) 95 92 65 55 32 Abl(h) 92 88 61 42 12 Abl(m) 94 83 57 47 11 Abl(T3151(h) 98 94 71 64 34 Abl(Y253F)(h) 101 103 74 59 26 ACK1(h) 120 128 116 97 79 ALK(h) 71 42 20 21 24 ALK4(h) 112 109 98 79 31 Arg(h) 106 95 76 43 21 Ar (m 103 105 94 67 34 ARK5(h) 102 107 83 70 55 Aurora-A(h) 74 76 49 45 14 Axl(h) 108 103 90 84 22 Blk(m) 108 108 62 40 36 Bmx(h 88 95 89 26 19 BrSK1(h 102 97 83 62 10 BrSK2(h) 81 81 67 61 18 BTK(h) 102 92 60 44 9 CaMKI(h) 92 88 57 43 23 CaMKII(r) 105 112 96 80 54 CaMKII(3(h) 99 101 87 69 44 CaMKII (h 91 105 100 106 97 CaMKIIB(h) 96 104 85 82 76 CaMKIV(h) 122 125 98 74 48 CaMKIS(h) 89 96 87 83 71 CDKI/c clinB(h) 116 119 107 75 18 CDK2/cyclinA(h) 118 120 108 90 35 CDK2/cyclinE(h) 93 97 76 74 8 CDK3/c clinE(h 54 51 43 40 5 CDKS/ 25(h) 77 79 72 79 7 CDK5/ 35(h) 136 130 77 123 32 CDK6/c clinD3(h) 115 104 88 174 80 CDK9/cyclin T1(h) 92 70 74 65 48 CHK2(h 101 112 102 101 39 CHK2(1157T)(h) 105 104 88 75 14 CHK2(R145W)(h) 120 116 101 103 48 CK1() 105 116 101 85 30 CKlyl(h) 98 97 73 46 15 (66) CK1 2(h) 96 100 59 40 11 CK1 3(h 101 96 49 34 4 CK16(h 112 102 82 65 6 cKit(D81611)(h) 118 115 94 92 64 cKit(D816V)(h) 104 107 87 79 80 cKit(h) 97 97 72 70 79 cKit(V560G)(h) 103 107 88 69 45 cKit(V654A (h) 94 102 77 70 47 CLK2(h) 109 103 99 97 74 cSRC(h) 100 108 109 90 31 DAPK1(h) 72 48 28 26 19 DAPK2 h) 67 74 51 53 45 DCAMKL2(h) 77 72 73 81 69 DRAK1(h 103 105 93 83 73 EGFR(L858R)(h) 110 118 113 85 34 EGFR(L861Q)(h) 96 107 90 75 52 EGFR(T790M)(h) 107 109 104 98 65 EGFR(T790M,L858R)(h) 103 99 101 87 63 E hAl(h) 123 118 120 99 82 EphA2(h) 105 112 127 124 53 EphA3(h) 101 96 83 82 84 EphA8(h) 110 109 92 94 57 E hBl(h 121 137 102 158 51 EphB3(h) 73 65 62 50 54 F, hB4(h) 103 107 92 85 82 Fer(h) 98 97 80 91 75 Fes h) 148 162 99 74 45 FGFRI(V561M)(h) 74 80 83 80 66 FGFR2(h) 93 91 68 72 59 FGFR2(N549H)(h) 108 112 102 86 48 FGFR3(h) 84 85 70 60 54 FGFR4 h) 113 80 44 65 62 F r(h 103 103 100 97 47 Fltl(h) 101 101 96 91 25 F1t3(D835Y (h) 95 96 99 100 60 F1t3(h) 116 107 101 98 34 F1t4(h) 106 101 86 68 17 Fms(h) 113 120 104 97 76 Fyn(h) 85 81 71 60 26 GRK7(h) 97 103 95 100 72 GSK3a(h) 81 88 52 39 7 GSK3 (h) 86 71 39 33 18 Haspin(h) 85 105 87 36 5 Hck(h) 92 82 60 41 11 HIPK2(h) 112 131 114 115 91 IKKa(h) 121 114 115 122 100 IKK (h) 110 114 100 86 32 IR(h) 79 53 30 43 49 (67) IRAK1(h) 40 39 45 49 46 Itk(h) 87 84 81 96 86 JAK2(h) 108 106 102 91 75 JAK3(h) 72 64 51 71 9 JNK3(h) 103 1103 100 80 60 Lck(h) 91 102 96 93 93 Lyn(h) 135 150 109 81 58 L n(m) 130 124 97 65 51 MAPK1(h , ERKI 99 97 72 66 41 MAPKAP-K2(h) 121 114 79 62 43 MAPKAP-K3(h) 103 102 100 110 61 MARK1(h) 103 108 100 68 40 MELK(h) 96 101 99 83 56 Met(b) 130 133 73 68 23 MKK4(m) 104 110 123 79 75 MKK7 (h) 83 92 79 82 48 MLCK(h) 97 95 101 97 94 MRCKa(h) 99 105 91 96 66 MRCK (h) 113 117 107 95 41 MSKI(h) 102 113 70 54 28 MSK2(h) 70 73 38 32 16 MSSK1(h) 105 65 48 50 17 MST3(h) 97 98 62 35 29 MuSK(h) 94 83 87 75 73 NEK1I(h) 92 101 94 71 41 NEK2(h) 45 45 46 52 18 NEK3(h) 74 67 66 88 51 NEK6(h) 71 67 54 41 8 NEK7(h) 105 106 96 87 40 NLK(h) 99 120 88 91 76 p70S6Kh) 101 97 100 74 28 PAK2(h) 115 114 110 106 86 PAK3(h) 95 76 47 48 26 PAK4(h) 103 89 66 100 74 PAK5(h) 118 105 99 76 33 PAK6(h) 98 86 85 71 27 PAR-lBa(h) 104 99 92 97 81 PASK(h) 71 72 73 74 61 PDGFRa(D842V)(h) 113 123 122 125 96 PDGFRa(V5611))(h 118 119 105 105 47 PDGFR (h) 61 69 55 47 56 PDK1(h) 126 129 95 68 55 PhKy2(h) 87 86 60 39 22 PI3-Kinase (h 99 95 34 4 -4 PI3-K.inase6(h) 99 90 44 11 -1 PI3-Kinase8(h) 89 87 24 12 9 Pim-1(h 93 87 86 49 27 Pim-2(h) 83 77 81 68 43 (68) Pim-3(h) 70 72 73 71 65 PKA(h 115 119 115 79 44 PKBa(h) 94 81 89 76 47 PKB(3(h) 111 109 65 42 17 PKB (h) 116 123 113 97 41 PKBa(h) 99 102 96 97 60 PKCJ3I(h) 98 100 92 91 54 PKC II(h) 105 106 100 93 62 PKC (h) 94 101 96 84 47 PKCS(h) 107 102 87 71 79 PKCE(h) 103 100 87 86 76 PKCO(h) 94 96 93 100 65 PKGIa(h) 98 99 100 75 36 Plk3(h) 115 106 97 94 84 PRAK(h) 38 48 27 20 16 PrKX(h 96 100 87 63 34 PTK5(h) 103 108 106 110 65 Ret (V804L)(h) 113 107 81 66 43 Ret(h) 120 113 96 82 34 Ret(V804M)(h) 122 120 105 110 89 ROCK-I(h) 107 108 95 87 50 Ron(h) 118 121 117 97 48 Rskl(h) 98 98 70 46 13 Rskl(r) 101 96 69 38 8 Rsk2(h) 109 95 52 31 17 Rsk3(h) 121 108 85 87 62 Rsk4(h) 84 76 42 15 5 SAPK2b(h) 103 100 103 110 96 SAPK3(h) 92 92 105 116 91 SAPK4(h) 111 108 110 104 96 SGK h 93 101 93 75 31 SGK2(h) 114 100 87 83 35 SIK h) 102 98 91 68 16 Src(1-530)(h) 109 116 107 95 7 SRPK1(h) 90 45 56 51 16 SRPK2(h) 94 87 84 83 72 Syk(h) 122 114 59 34 25 TBKl(h) 87 97 98 83 41 Tie2(h) 110 113 64 61 54 Tie2(R849W)(h) 81 42 38 50 46 Tie2 Y897S)(h) 69 43 31 28 25 TLK2(h) 95 92 83 94 74 TrkA(h) 85 95 34 7 16 TrkB(h) 128 132 139 79 49 TSSK1(h 103 105 93 85 67 TSSK2(h) 102 103 101 92 51 Txk(h) 99 110 121 111 94 (69) ULK2(h) 117 103 50 69 63 WNK3(h) 105 114 112 107 81 Yes(h) 110 110 105 107 58 ZAP-70(h) 74 58 52 65 57 ZIPK(h) 108 97 79 73 60 Example 4 Effect of Meta-THc on P13K activity 1001511 The inhibitory effect of Meta-THc on human PI3K-J3, PI3K-y, and PI3K-c5 activity was examined according to the procedures and protocols of Example I.
All compounds were tested at at 1, 5, 25 and 50 g/ml. The results are presented graphically as Figure 4 comparing the kinase inhibition of P13K activity as compared with test results against additional protein kinases implication in cancer, angiogenesis and inflammation.

Example 5 Inhibition of PGE2 and Nitric oxide by Meta-THc 1001521 LPS activated RAW 264.7 cells were assayed for PGE2 and nitric oxide in the medium.

[00153) Materials - Meta-THc and its analogs were supplied by Metagenics (San Clemente, CA). LPS was purchased from Sigma (Sigma, St. Louis, MO). The concentration of Meta-THc was calculated based on the activities of cis and trans diastereomers of each of the three predominant n-, ad- and co- Meta-TI-Ic analogs. All other chemicals were of analytical grade purchased from Sigma (St. Louis, MO).

[001541 Cell Culture and Stimulation - The murine macrophage RAW 264.7 cell line was purchased from ATCC (Manassas, VA) and maintained according to their instructions.
Heat-inactivated fetal bovine serum (FBS), penicillin and streptomycin solution, and Dulbecco's Modification of Eagle's Medium (DMEM) were purchased from Mediatech (Herndon, VA). Cells were grown and subcultured in 96-well plates at a density of 8x 10`' cells per well reaching 90% confluence the next day. Test compounds were added to the cells in serum free medium at a final concentration of 0.1% dimethyl sulfoxide (DMSO).
Following one hour of incubation with the test compounds, LPS (1 g/ml) or DMEM

(70) medium alone was added to the cells and incubation continued for the indicated times. After the 4 hr stimulation with LPS, the media was collected and measured PGE2 (Assay Designs, Ann Harbor, MI). For the measurement of nitric oxide production, the media was collected after 20 hr of LPS stimulation and nitratate/nitrite levels were measured (Cayman Chemicals, Ann Harbor, MI).

[001551 Results - Meta-THc inhibited PGE2 and nitric oxide production in LPS
activated RAW 264.7 cells and are presented in Figure 5.

Example 6 Lack of Direct COX-2 Inhibition by Meta-THc [00156) The objective was to determine the direct inhibition of COX-2 enzymatic activity.

[00157) Materials - Test compounds were prepared in DMSO and stored at -20 C.
Meta-THc was supplied by Metagenics (San Clemente, CA). The commercial formulation of celecoxib (Celebrex , G.D. Searle & Co., Chicago, IL) was used and all concentrations were based on the active material, although recipients were included. LPS was purchased from Sigma-Aldrich (St. Louis, MO).

[00158) Cell Culture - The murine macrophage RAW 264.7 cell line was purchased from ATCC (Manassas, VA) and maintained according to their instructions. Cells were subcultured in 96-well plates at a density of 8x 104 cells per well and allowed to reach 90%
confluence. LPS (1 l.ig /ml) or DMEM alone was added to the cell media and incubated for 20 hrs. Test compounds with LPS were added to the cells in serum free media at a final concentration of 0.1% DMSO. Following one hour of incubation with the test compounds, the cell media were removed and replaced with fresh media with test compounds with LPS
(1 pg/ml) and incubated for 1 hr. The media were removed from the wells and analyzed for the PGE2 synthesis.

[00159) PGE2 assay - A commercial, non-radioactive procedure for quantification of PGE2 was employed (Cayman Chemical, Ann Arbor, MI). Samples were diluted 10 times in EIA buffer and the recommended procedure of the manufacturer was used without (71) modification. The PGE2 concentration was represented as picograms per ml. The manufacturer's specifications for this assay include an intra-assay coefficient of variation of <10%, cross reactivity with PGD2 and PGF2 of less than 1% and linearity over the range of - 1000 pg ml-1.

[001601 Results: The results indicate that Meta-THc was not a specific COX-2 enzymatic inhibitor and are presented in Figure 6.

Example 7 Inhibition of COX-2 protein by Meta==THc [001611 Cellular extracts from RAW 264.7 cells stimulated with LPS were assayed for COX-2 protein by Western blot.

[001621 Materials - Test compounds were prepared in DMSO and stored at -20 C.
Meta-THc was supplied by Metagenics (San Clemente, CA). Antibodies generated against COX-2 were purchased from Cayman Chemical (Ann Arbor, MI). Antibody generated against Actin was purchased from Sigma. Secondary antibodies coupled to horseradish peroxidase were purchased from Amersham Biosciences (Piscataway, NJ).

1001631 Cell Culture - The murine macrophage RAW 264.7 cell line was purchased from ATCC (Manassas, VA) and maintained according to their instructions. Test compounds were added to the cells in serum free medium at a final concentration of 0.1 %
DMSO. Following one hour of incubation with the test compounds, LPS (1 1g/ml) or DMEM alone was added to the cell wells and incubation continued forl6hrs.

[001641 Western Blot analysis of COX-2: Cells were washed with cold PBS and lysed with 100 pl of lysis buffer (Bio-Rad). After denaturing, the samples were separated on SDS-PGE and transferred to nitrocellulose membrane. Incubation with the primary antibody followed by the secondary antibody was for one hr each at room temperature.
Chemiluminescence was performed using the SuperSignal West Femto Maximum Sensitivity Substrate from Pierce Biotechnology (Rockford, IL) Western blot image was developed by autoradiogram (Kodak, BioMax film). Densitometry was performed using Kodak software.

(72) [001651 Results: The results indicated that Meta-THc inhibited COX-2 protein expression in LPS activated RAW 264.7 cells. The results are presented graphically in Figure 7.

Example 8 NF-KB DNA Binding [001661 Nuclear extracts from RAW 264.7 cells stimulated with LPS for 2 hours were assayed for NF-KB activity.

[00167] Materials - Test compounds were prepared in DMSO and stored at -20 C.
Meta-THc was supplied by Metagenics (San Clemente, CA), Parthenolide was purchased from Sigma-Aldrich (St. Louis, MO).

[001681 Cell Culture - The murine macrophage RAW 264.7 cell line was purchased from ATCC (Manassas, VA) and maintained according to their instructions. Cells were subcultured in 6-well plates at a density of 1.5 x 106 cells per well and allowed to reach 90%
confluence, approximately 2 days. Test compounds were added to the cells in serum free media at a final concentration of 0.1 % DMSO. Following one hour of incubation with the test compounds, LPS (I g/ml) or DMEM alone was added to the cell media and incubation continued for an additional 2 hours.

[001691 NF-KB Binding - Nuclear extracts were prepared essentially as described by Dignam, et al [Nucl Acids Res 11:1475-1489, (1983)]. Briefly, cells are washed twice with cold PBS, then Buffer A (10 mM HEPES, pH 7.0; 1.5 mM MgCl2; 10 mM KCI; 0.1 %
NP-40; aprotinin 5 g/ml; pepstatin A I .tg/ml; leupeptin 5 g/ml;
phenylmethanesulfonyl fluoride 1 mM) was added and allowed to sit on ice for 15 minutes. The lysis step was repeated with buffer A. The supernatant following centrifugation at 10,000 x g for 5 minutes at 4 C was the cytoplasmic fraction. The remaining pellet was resuspended in Buffer C (20 mM HEPES, pH 7.0; 1.5 mM KCI; 420 mM KCI; 25% glycerol; 0.2 M
EDTA; aprotinin 5 g/ml; pepstatin A I g/ml; leupeptin 5 g/ml;
phenylmethanesulfonyl fluoride 1 mM) and sonicated (5x 2sec with S see interval The nuclear extract fraction was collected as the supernatant following centrifugation at 10,000 x g for 5 minutes at 4 C.
DNA binding activity of the nuclear extracts was assessed using electrophoretic mobility (73) shift assays (EMSA) with ATP (p32) labelled NF-KB consensus oligonucleotide (5' AGTTGAGGGGACTTTC-CCAGGGC). Gel was exposed to autoradiography, [001701 Results: The results indicated that Meta-THc inhibited nuclear translocation of NF-KB in LPS activated RAW 264.7 cells. The results are presented in Figure 8.
Example 9 Inhibition of MMP-13 expression 1001711 Human chondrosarcoma cells were assayed for MMP-13 secretion in the medium.

[001721 Materials -human TNFa and IL-10 were obtained from Sigma (St Louis, MO). The concentration of Meta-THc was calculated based on the activities of cis and trans diastereomers of each of the three predominant n-, ad- and co- Meta-THc analogs as well as other minor RIAA analogs. Assay kits for MMP-13 measurement were purchased from Amersham Biosciences (Piscataway, NJ).

1001731 Cell culture: The human chondrocyte cell line, SW 1353 was purchased from ATCC (Manassas, VA) and maintained in L- 15 medium in the presence of 10%
serum according to manufacturer instructions. Cells were grown and subcultured in 96-well plates at a density of 8x 104 cells per well and allowed to reach -80% confluence overnight. Test compounds in medium were added to the cells at a final concentration of 0.1%
DMSO.
Following one hour of incubation with the test compounds, TNFa (lOng/ml) or IL-1[3 (l Ong/ml) or medium alone was added to the cell wells and incubation continued for 20-24 hours. The supernatant media was subsequently collected for MMP-13 determination (Amersham Biosciences, Piscataway, NJ).

1001741 Results: Meta-THc dose dependently inhibited TNFa and IL-113 induced MMP-13 expression in SW 1353 cells. The results are presented as Figure 9 Example 10 Inhibition of PGE2 and Nitric oxide by Meta-THc analogs [001751 LPS activated RAW 264.7 cells were assayed for PGE2 and nitric oxide in the medium.

(74) [00176] Materials - as described in Example 5 [00177] Cell Culture and Stimulation - as described in Example 5.

[00178] Results - Meta-THc analogs inhibited PGE2 and nitric oxide production in LPS activated RAW 264.7 cells. The results are presented in Figure 10.

Example I I

Meta-THc analog inhibition of inflammation associated kinases [00179] The objective was to determine whether Meta-THc components inhibit inflammation associated kinases.

[00180] Materials - as described in Example 1 [00181] Results - The dose dependent inhibitory effects of Meta-THc components on selected kinases are presented in Figures 11 - 13.

Example 12 Meta-THc analog inhibition of angiogenesis associated Arg tyrosine kinase [00182] The objective was to determine whether Meta-THc components inhibited the angiogenic associated ARG tyrosine kinase.

[00183] Materials - as described in Example 1.

[00184] Results - The dose dependent inhibitory effects of Meta-THc components on selected kinases are presented in Figures 14.

Example 13 Meta-THc analog inhibition of colon cancer associated kinases [00185] The objective was to determine whether Meta-THc components inhibited the colon cancer associated kinases.

[00186] Materials - as described in Example 1.

(75) [001871 Results - The dose dependent inhibitory effects of Meta-THc components on selected kinases are presented in Figures 15.

Example 14 Effects of test compounds in a collagen induced rheumatoid arthritis murine model [001881 This example demonstrated the efficacy of Meta-THc in reducing inflammation and arthritic symptomology in a rheumatoid arthritis model, such inflammation and symptoms being known to mediated, in part, by a number of protein kinases.

[001891 The Model - Female DBA/J mice (10/group) were housed under standard conditions of light and darkness and allow diet ad libitum. The mice were injected intradermally on day 0 with a mixture containing 100 g of type 11 collagen and 100 pg of Mycobacterium tuberculosis in squalene. A booster injection was repeated on day 21.
Mice were examined on days 22 - 27 for arthritic signs with nonresponding mice removed from the study. Mice were treated daily by gavage with test compounds for 14 days beginning on day 28 and ending on day 42. Test compounds, as used in this example were Meta-THc at 10 mg/kg (lo), 50 mg/kg (med), or 250 mg/kg (hi); celecoxib at 20 mg/kg; and prednisolone at 10 mg/kg.

[001901 Arthritic symptomology was assessed (scored 0 - 4) for each paw using a arthritic index as described below. Under this arthritic index 0 = no visible signs; I =
edema and/or erythema: single digit; 2 = edema and or erythema: two joints; 3 = edema and or erythema: more than two joints; and 4 = severe arthritis of the entire paw and digits associated with ankylosis and deformity.

[001911 Histological examination - At the termination of the experiment, mice were euthanized and one limb, was removed and preserved in buffered formalin. After the analysis of the arthritic index was found to be encouraging, two animals were selected at random from each treatment group for histological analysis by H&E staining.
Soft tissue, joint and bone changes were monitored on a four point scale with a score of 4 indicating severe damage.

(76) 1001921 Cytokine analysis - Serum was collected from the mice at the termination of the experiment for cytokine analysis. The volume of sample being low (- 0.2-0.3 ml/mouse), samples from the ten mice were randomly allocated into two pools of five animals each. This was done so to permit repeat analyses; each analysis was performed a minimum of two times. TNFa and IL-6 were analyzed using mouse specific reagents (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Only five of the twenty-six pools resulted in detectable levels of TNF-a; the vehicle treated control animal group was among them.

[001931 Results -Figure 16 displays the effects of Meta-THe on the arthritic index.
Here, significant reductions were observed for celecoxib (days 32 - 42), Meta-THc at 250 mg/kg (days 34 - 42) and Meta-THc at 50 mg/kg (days 34 - 40), also demonstrating the effectiveness of Meta-THc as an antiarthritic agent.

Example 15 Effects of test compounds on cancer cell proliferation in vitro [001941 This experiment demonstrated the direct inhibitory effects on cancer cell proliferation in vitro for a number of Meta-THc test compounds of the instant invention.
[001951 Methods - The colorectal cancer cell lines HT-29, Caco-2 and SW480 were seeded into 96-well plates at 3x103 cells/well and incubated overnight to allow cells to adhere to the plate. Each concentration of test material was replicated eight times. Seventy-two hours later, cells were assayed for total viable cells using the CyQUANT
Cell Proliferation Assay Kit. Percent decrease in viable cells relative to the DMSO
solvent control was computed. Graphed values are means of eight observations 95%
confidence intervals.

[001961 Results - Figure 17 graphically presents the inhibitory effects of Meta-THc compounds .

Example 16 Detection of Meta-THc in serum following oral dosage (77) [00197] The purpose of this experiment was to determine whether Meta-THc was metabolized and detectable following oral dosage in humans.

[00198] Methods - Following a predose blood draw, five softgels (188mg THIAA/
softgel) delivering 940 mg of Meta-THc as the free acid (PR Tetra Standalone Softgel. OG#
2210 KP-247. Lot C42331111) were consumed and immediately followed by a container of fruit yogurt. With the excpetion of decaffinated coffee, no additional food was consumed over the next four hours following Meta-THc ingestion. Samples were drawn at 45 minute intervals into Corvac Serum Separator tubes with no clot activator. Samples were allowed to clot at room temperature for 45 minutes and serum separated by centrifugation at 1800 x g for 10 minutes at 4 C. To 0.3 ml of serum 0.9 ml of MeCN containing 0.5%
HOAc was added and kept at -20 C for 45-90 minutes. The mixture was centrifuged at 15000 x g for minutes at 4 C. Two phases were evident following centrifugation two phases were evident; 0.6 ml of the upper phase was sampled for HPLC analysis. Recovery was determined by using spiked samples and was greater than 95%.

[00199] Results - The results are presented graphically as Figures 18 - 20.
Figure 18 graphically displays the detection of Meta-THc in the serum over time following ingestion of 940 mg of Meta-THc. Figure 19 demonstrates that after 225 minutes following ingestion, Meta-THc was detected in the serum at levels comparabe to those Meta-THc levels tested in vitro. Figure 20 depicts the metabolism of Meta-THc by CYP2C9* 1.

Example 17 Evaluation of the Anti-angiogenic Activities of Hops Derivatives [00200] Ex vivo rat aortic ring angiogenesis assay [00201] Test materials and chemicals - The test materials isoalpha acid (IAA), rho-isoalpha acid (R.IAA), tetrahydroisoalpha acid (THIAA), hexahydroisoalpha acid (HHIAA), beta acids (BA) and xanthohumol (XN) were supplied by Metaproteomics, Gig Harbor, WA. All standard chemicals, media and reagents, unless otherwise noted, were purchased from Sigma, St Louis, MO.

[00202] Methodology - Cleaned rat aortic rings were embedded into rat tail interstitial type I collagen gel (1.5 mg/ml). This final collagen solution was obtained by mixing 7.5 (78) volumes of type I collagen (2 mg/ml, Collagen R; Serva, Heidelberg, Germany) with 1 volume of 10 times concentrated DMEM, 1.5 volumes of sodium bicarbonate solution (15.6 mg/ml), and 0.1 volume of sodium hydroxide solution (1 M) to adjust the pH to 7.4.
Collagen-embedded rat aortic rings were processed in cylindrical agarose wells and placed in triplicate in 60-mm bacteriologic polystyrene dishes containing 8 ml of serum-free MCDB-131 (Invitrogen) supplemented with 25 mM NaHCO3, 1% glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. These ex vivo organo-typic cultures were treated with single compound. After 9 days of culture at 37 C under an air-C02 (95%:5%) atmosphere, the aortic rings were photographed under an optic microscope (25 magnification, Carl Zeiss AxioCam HR Workstation, K.S 100 3.0 software).
Neovascularization was evaluated as a marker of the observed angiogenic response.

[00203] Statistical analysis - Analysis of variance was performed on the six observations per treatment for the controls and two test concentrations after normalizing to the dimethyl sulfoxide control. The probability of a type I error was set at the nominal five percent level.

Table 12. Relative Number of Vessels vs Dimethyl Sulfoxide Controls Dose Test Material 20 pg/mL, 5.0 pg/mL
Isoalpha acid 113** 108 Rho-isoalpha acid 16.2** 75.2**
Tetrahydro isoalpha acid 0.00** 15.9**
Hexahydroisoalpha acid 81.1** 98.5 Beta acids 52.0** 96.0 Xanthohumol 100 95,9 *p<0.05; **p<0.01 [00204] Results - Both RIAA and THIAA effectively inhibited vessel growth at both 20 and 5 gh/mL [SHOULD THIS BE 5 or 50 g/ml,?], while HHIAA and BA were active only at the 20 1g/mL concentration. Xanthohumol was not active in this assay and IAA actually increased vessel growth at the higher concentration.

[00205] Migration wound healing assay (79) [00206] Methodology - A day before the assay, 5x105 endothelial cells were plated in 6-well plates and grown in adequate complete medium over night. Confluent HUVEC
monolayers were then scraped to create a wound. Cells were the treated wit 20 ug/mI of each drug. After wounding and 6 hours later, two different fields of each wound were photographed with a phase-contrast microscope. Measurements of the width of each wound were made in each experimental condition. At the start of the experiment, the wound size was measured and scored as 100%. After 6 hours, the width of the remaining wound was measured and average percent wound closure was calculated.

Table 13. Relative Percent Wound Closure at Six Hours vs Dimethyl Sulfoxide Controls Dose Test Material 20 g/mL
Isoalpha acid 74**
Rho-isoalpha acid 80*
Tetrahydro isoalpha acid 61**
Hexahydroisoalpha acid 106 Beta acids 68**
Xanthohumol 45**
*p<0.05; * *p<0.01 [00207] Results - Of the six test materials, only HHIAA failed to inhibit wound closure. The most active of the test materials was XN, followed by THIAA, BA, IAA and RIAA.

[00208] Proliferation assay [00209] Methodology - A day before the assay, lx104 endothelial cells were plated in quadruplicate in 24-well plates ad grown in adequate complete medium over night. Cells were then treated with 10 ug/ml and 20 ug/ml of each drug. After 6 hours, 48 hours and 72 hours cells were then resuspended and sonicated in 200 ul PBS. 100 ul of the sonicated samples were transferred to 96-well microplates and 100 ul of Hoechst 33258 (2 ug/ml) was added. For the standard curve, 100 ul of DNA standards with concentrations of 0.3125, 0.625, 1.25, 2.15, 5, 10 and 20 ug/ml were used. The dilutions and concentrations of the dyes were chosen to yield appropriate dye/base pair ratios that are crucial to obtain maximal linearity and sensitivity of the DNA quantification assays. After an incubation time of -10 (80) min, fluorescence intensities were measure. All investigations were generally performed at room temperature with the solutions protected from light. Spectrofluorimetric measurements were performed with Spectramax Gemini XS. Hoechst 33258 was excited at 360 nm and fluorescence emission was detected at 458 nm. Florescence values were converted into DNA concentrations according to the fluorescence intensities of DNA
standard calibration curves.

Table 14. Relative DNA Content vs Dimethyl Sulfoxide Controls 24 Hours 48 Hours 72 Hours Test Material g/mL g/mL g/mL g/mL g/mL g/mL
Isoalpha acid 103 97 100 98 100 98 Rho-isoalpha acid 96 84** 93* 75** 80** 52**
Tetrahydro isoalpha acid 95 82** 88** 79** 79** 40**
Hexahydroisoalpha acid 80** 71** 63** 55** 57** 35**
Beta acids 103 97 100 98 98 97 Xanthohumol 95 66** 82** 57** 71** 42**
*p<0.05; **p<0.01 1002101 Results - HHIAA was most active among the test agents, inhibiting proliferation at both concentrations and all time points. THIAA and XN
provided similar inhibition by 72 hours followed by RIAA. Neither BA nor IAA effectively inhibited proliferation in this assay.

[002111 Conclusions Table 15, Summary of Effects Assays Test Material Aortic Angiogenesis Migration Proliferation Average Isoalpha acid Not Active -25% Not Active -Rho-isoalpha acid -80% -20% -50% -50%
Tetrahydro isoalpha acid -100% -60% -60% -73%
Hexahydroisoalpha acid -95% Not -60% -Active Beta acids -40% -35% -40% -38%

(81) Xanthohumol Not Active -60% -60% -[00212] Of the six test materials, three exhibited anti-angiogenic activity in all three assays (Table 15). THIAA was the most potent of the three followed by RIAA and BA.
[002131 The invention now having been fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

(82)

Claims (23)

1. A method to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.

2. The method of Claim 1, wherein the substituted 1,3-cyclopentadione compound is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumtilone, and tetrahydro-adhumulone.

3. The method of Claim 1, wherein the protein kinase modulated is selected from the group consisting of Ab1(T315I), Aurora-A, Bone marrow tyrosine kinase gene in chromosome X (Bmx), Bruton's tyrosine kinase (BTK), Calcium/calmodulin-dependent protein kinase-I (CaMKI), CaMKI.delta., Colon carcinoma kinase-2/cyclinA (CDK2/cyclinA), CDK3/cyclinE, CDK9/cyclin T1, Casein kinase-1(.gamma.) (CK1(.gamma.), CK1.gamma.1, CK1.gamma.2, CK.1.gamma.3, CK1.delta., cSRC, Death-associated protein kinase-1 (DAPK1), DAPK2, DRAK1, Ephrin receptor-A2 (EphA2), EphA8, Proto-oncogene tyrosine-protein kinase FER (Fer), Fibroblast growth factor receptor-2 (FGFR2), FGFR3, Proto-oncogene tyrosine-protein kinase FGR (Fgr), Tyrosine-protein kinase receptor FLT4 (Flt4), c-Jun NH2-terminal kinase-3 (JNK3), phosphatidylinositol-3-kinase (PI3K), Proto-oncogene serine/threonine-protein kinase-1 (Pim-1), Pim-2, Protein kinase A (PKA), PKA(b), Protein kinase B-.beta. (PKB.beta.), PKB.alpha., PKB.gamma., p38-regulated/ activated protein kinase (PRAK), human X chromosome-encoded protein kinase X
(PrKX), Ron, ribosomal S6 kinase 1 (Rsk1), ribosomal S6 kinase 2 (Rsk2), serine/threonine kinase 2(SGK2), spleen tyrosine kinase (Syk), Tyrosine kinase with immunoglobulin and EGF repeats-2 (Tie2), TrkA, and TrkB.

4. The method of Claim 1, wherein the cancer responsive to kinase modulation is selected from the group consisting of bladder, breast, cervical, colon, lung, lymphoma, melanoma, prostate, thyroid, and uterine cancer.

5. The method of Claim 1, wherein the substituted 1,3-cyclopentadione compound is administered in a composition which further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and (83) absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

6. The method of Claim 6, wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

7. The method of Claim 1, wherein the substituted 1,3-cyclopentadione compound is administered in combination with a chemotherapeutic agent.

8. A method to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.

9. The method of Claim 7, wherein the substituted 1,3-cyclopentadione compound is selected from the group consisting of dihydro- (Rho) isoalpha acids; tetra-hydroisoalpha acids; hexa-hydroisoalpha acids; beta acids; their individual analogs; and mixtures thereof.

10. The method of Claim 7, wherein the substituted 1,3-cyclopentadione compound is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

11. The method of Claim 7, wherein the protein kinase modulated is selected from the group consisting of ATK, Mitogen-activated protein kinase (MAPK), p38-regulated/activated protein kinase (PRAK), phosphatidylinositol-3-kinase (PI3K), Protein kinase C (PKC), Glycogen synthase kinase (GSK), Epidermal growth factor receptor (FGFR), BTK, Phosphoinositide-dependent kinase (PDK), Spleen tyrosine kinase (SYK), Mitogen- and stress-activated protein kinase (MSK) and I-kB kinase-b (IKKb).

12. The method of Claim 7, wherein the substituted 1,3-cyclopentadione compound is administered in a composition which further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and (84) absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

13. The method of Claim 11, wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

14. The method of Claim 7, wherein the substituted 1,3-cyclopentadione compound is administered in combination with an anti-angiogenic agent.

15. A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a cis-n-tetrahydro-isoalpha acid (TH5) as the only substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates a cancer associated protein kinase.

16. A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amounts of one or more (n) analogs of substituted 1,3-cyclopentadione compound and optionally one or more (ad) analogs of substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates a cancer associated protein kinase.

17. A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amount of one or more (co) analogs of substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates a cancer associated protein kinase.

18. A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a cis-n-tetrahydro-isoalpha acid (TH5) as the only substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates an angiogenesis associated protein kinase.

(85)

19, A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amounts of one or more (n) analogs of substituted 1,3-cyclopentadione compound and optionally one or more (ad) analogs of substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates an angiogenesis associated protein kinase.

20. A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amount of one or more (co) analogs of substituted 1,3-cyclopentadione compound in the composition; wherein said therapeutically effective amount modulates an angiogenesis associated protein kinase.

21. A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of only one analog of a substituted 1,3-cyclopentadione compound;
wherein said therapeutically effective amount modulates a cancer associated protein kinase.

22. A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of only one analog of a substituted 1,3-cyclopentadione compound; wherein said therapeutically effective amount modulates an angiogenesis associated protein kinase.

23. The composition of claims 21 or 22, where in the analog of a substituted 1,3-cyclopentadione compound is selected from the group consisting of rho (6S) cis n iso-alpha acid, rho (6S) cis n iso-alpha acid, rho (6R) cis n iso-alpha acid, rho (6R) trans n iso-alpha acid, rho (6S) trans n iso-alpha acid, rho (6R) cis rho n iso-alpha acid, rho (6S) cis n iso-alpha acid, (6S) trans rho n iso-alpha acid, rho (6R) trans n iso-alpha acid, rho (6S) cis co iso-alpha acid, rho (6R) cis co iso-alpha acid, rho (6R) trans co iso-alpha acid, rho (6S) trans co iso-alpha acid, rho (6R) cis co iso-alpha acid, rho (6S) cis co iso-alpha acid, rho (6S) trans co iso-alpha acid, rho (6R) trans co iso-alpha acid, rho (6S) cis ad iso-alpha acid, rho (86) (6R) cis ad iso-alpha acid, rho (6R) trans ad iso-alpha acid, rho (6S) trans ad iso-alpha acid, rho (6R) cis ad iso-alpha acid, rho (6S) cis ad iso-alpha acid, rho (6S) trans ad iso-alpha acid, rho (6R) trans ad iso-alpha acid, tetrahydro cis n iso-alpha acid, tetrahydro trans n iso-alpha acid, tetrahydro cis n iso-alpha acid, tetrahydro trans n iso-alpha acid, tetrahydro cis co iso-alpha acid, tetrahydro trans co iso-alpha acid, tetrahydro cis co iso-alpha acid, tetrahydro trans co iso-alpha acid, tetrahydro cis ad iso-alpha acid, tetrahydro trans ad iso-alpha acid, tetrahydro cis ad iso-alpha acid, tetrahydro trans ad iso-alpha acid, hexahydro (6S) cis n iso-alpha acid, hexahydro (6R) cis n iso-alpha acid, hexahydro (6R) trans n iso-alpha acid, hexahydro (6S) trans n iso-alpha acid, hexahydro (6R) cis n iso-alpha acid, hexahydro (6S) cis n iso-alpha acid, hexahydro (6S) trans n iso-alpha acid, hexahydro (6R) trans n iso-alpha acid , hexahydro (6S) cis co iso-alpha acid, hexahydro (6R) cis co iso-alpha acid, hexahydro (6R) trans co iso-alpha acid, hexahydro (6S) trans co iso-alpha acid, hexahydro (6R) cis co iso-alpha acid, hexahydro (6S) cis co iso-alpha acid, hexahydro (6S) trans co iso-alpha acid, hexahydro (6R) trans co iso-alpha acid, hexahydro (6S) cis ad iso-alpha acid, hexahydro (6R) cis ad iso-alpha acid, hexahydro (6R) trans ad iso-alpha acid, hexahydro (6S) trans ad iso-alpha acid, hexahydro (6R) cis ad iso-alpha acid, hexahydro (6S) cis ad iso-alpha acid, hexahydro (6S) trans ad iso-alpha acid, hexahydro (6R) trans ad iso-alpha acid, lupolone, colupulone, adlupulone, prelupulone, postlupulone, and xanthohumol.

(87)